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Amyotrophic lateral sclerosis (ALS) is a complex, progressive and fatal 
motor neuron disease. There are currently no effective treatments for ALS. 
P2X7 receptor is a ligand-gated cation channel, which is activated by 
extracellular adenosine 5’-triphosphate (ATP) and present in the periphery 
and in the central nervous system (CNS). Among different factors 
contributing to the progression of ALS, the involvement of ATP-P2X7 
signalling axis plays a role in this disease through the activation of microglia 
and astrocytes to promote death of motor neurons. Whilst the ectoATPase 
CD39, which hydrolyses extracellular ATP, is down-regulated in ALS 
leading to the potential accumulation of extracellular ATP and subsequent 
activation of the P2X7 receptor channel to promote disease. In order to 
understand the roles of the ATP-P2X7 signalling axis in ALS, cellular 
models that closely resemble ALS-associated models would be beneficial to 
establish. Furthermore, the use of CNS-penetrant P2X7 antagonists might 
further establish the role of the P2X7 receptor in ALS progression in vivo. 
Thus, this study aims to investigate P2X7 receptor and CD39 on murine 
EOC13 microglia to determine if it may serve as a suitable in vitro model of 
these molecules on microglia in ALS (Chapter 2). Moreover, this study aims 
to determine if CNS-penetrant P2X7 antagonists JNJ-47965567 ameliorates 
disease progression in SOD1 ALS mice (Chapter 3).  
xi  
In Chapter 2, P2X7 and CD39 expression was determined by qPCR and flow 
cytometry. P2X7 activity was measured by a fixed-time ethidium+ uptake 
assay. CD39 activity was measured using the molybdite assay. qPCR and 
flow cytometry confirmed the presence of high amount of P2X7 receptor and 
a low amount of CD39 on EOC13 microglia. Pre-incubation of EOC13 
microglia with the CNS penetrant P2X7 antagonist, JNJ-47965567, impaired 
ATP-induced cation uptake confirming the presence of functional P2X7 on 
these cells. This study also revealed negligible ectoATPase activity on 
EOC13 cells. These results demonstrate that murine EOC13 microglia 
express a relatively high level of P2X7 but low level of CD39 when 
compared to murine spleen cells. This pattern reflects that of ALS-associated 
microglia, indicating EOC13 microglia may serve as a potential model to 
study the ATP-P2X7 signalling axis in microglial events relating to ALS. 
In Chapter 3, to investigate the therapeutic efficacy of CNS-penetrant P2X7 
antagonists JNJ-47965567, SOD1G93A transgenic mice were injected 
intraperitoneally with JNJ-47965567 or vehicle solution from d 101-103 
(i.e., disease onset) until end-stage. SOD1G93A mice were monitored for the 
progression of ALS by measuring body weight, clinical score, motor 
coordination and survival. In the current study, the CNS-penetrant P2X7 
receptor antagonist JNJ-47965567 did not alter disease progression in ALS 
SOD1G93A mice. This result was the same in either male or female SOD1G93A 
xii  
mice, or when combined into treatment groups of both genders. Thus, this 
study suggests that the blockade of periphery and CNS P2X7 receptors is 










































1.1 Amyotrophic lateral sclerosis 
1.1.1 Introduction 
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's or Charcot 
disease, was first described by Jean-Martin Charcot in 1874 (Rowland 2001). 
ALS is a progressive motor neuron disease in which motor neurons die in 
the motor cortex, brain stem, and spinal cord (Boillee et al. 2006)  
(Figure 1.1). Two forms of ALS have been identified; sporadic ALS (sALS) 
and familial ALS (fALS) (Harikrishnareddy et al. 2015). Almost 90% of 
ALS patients suffer from the sporadic form and only 10% patients suffer 
from the familial form (Harikrishnareddy et al. 2015). Two to three people 
suffer from ALS per 100,000 (Al-Chalabi and Hardiman 2013). The 
incidence rate of ALS is higher in males than in females, possessing a risk 
ratio of 1:350 and 1:400 for males and females respectively (Al-Chalabi and 
Hardiman 2013). ALS is a fatal disorder in which most patients do not 
survive more than 3 to 5 years following diagnosis (Wijesekera and Leigh 
2009). Despite decades of research, riluzole (Bensimon et al. 1994) and 
edaravone (Abe et al. 2014) remain the only drugs approved by Food and 
Drug Administration, however both have limited efficacy on ALS patients. 
Thus, there is an urgent need of more effective drugs for the treatment of this 




Figure 1.1 Affected areas in the central nervous system (CNS) in amyotrophic lateral 
sclerosis (ALS). (A) In normal conditions, skeletal muscles receive signals from the 
brain. (B) In ALS, the death of motor neurons in the motor cortex, brainstem and spinal 
cord prevents signal transfer to the skeletal muscles resulting in muscle weakness and 
paralysis. 
The hallmark of ALS is the presence of lower and upper motor neuron signs 
and symptoms. ALS can present with four different types of onset; limbic 
onset, bulbar onset, primary lateral sclerosis and progressive muscular 
atrophy (Kiernan et al. 2011, Al-Chalabi and Hardiman 2013). In limbic 
onset, voluntary muscles of both upper and lower limbs are affected causing 
muscles weakness, fasciculation, spasticity, wasting and tendon reflexes. 
Bulbar onset is mainly characterised by difficulty in speaking, breathing and 
swallowing. Primary lateral sclerosis and progressive muscular atrophy 








A. Normal B. ALS
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1.1.2 Disease Mechanisms in ALS  
The disease mechanism in ALS is a complex process involving multiple 
factors. Despite numerous studies, disease pathogenesis in ALS is still not 
clear. Gene mutation, epigenetic regulation and environmental exposure 
have been associated with ALS causes (Paez-Colasante et al. 2015). Gene 
mutation is considered one of the major reasons for the occurrence of fALS. 
Mutation in genes such as C9orf72, SOD1, TARDBP (TDP-43) and FUS 
occur frequently, however mutation in 40 other genes have also been 
associated with ALS (Al-Chalabi et al. 2017). Among all genetic mutations, 
mutation in C9orf72 is the most common, accounting for 40-50% of total 
familial cases. Mutation in SOD1 accounts for 20% of fALS, TARDBP and 
FUS account for 1-5% of fALS, and ANG accounts for <1% of fALS 
(Robberecht and Philips 2013). Although genetic mutation is closely 
associated with fALS, studies conducted in monozygotic twins discovered 
an association of epigenetic regulation such as deoxyribonucleic acid (DNA) 
methylation, histone remodeling, ribonucleic acid (RNA) editing and  
non-coding RNAs in ALS patients with no family history of ALS  
(Paez-Colasante et al. 2015). Along with genetic contribution, different 
environmental factors are also known to contribute in the onset of ALS  
(Al-Chalabi and Hardiman 2013).  
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1.1.2.1 Mutations in the gene coding Cu-Zn superoxide dismutase-1 
(SOD1)  
The SOD1 gene was the first gene identified as the genetic cause of ALS 
(Rosen et al. 1993). The SOD1 gene is located on chromosome 21 in humans. 
Five exons in this chromosome encode the Cu-Zn superoxide dismutase-1 
(SOD1) subunit, a protein consisting of 153 amino acids, which when bound 
with copper and zinc forms a SOD1 homodimer (Turner and Talbot 2008). 
The dimeric form of SOD1 acts as an antioxidant, metabolising the toxic 
radical superoxide to molecular oxygen and hydrogen peroxide (Rosen et al. 
1993, Kaur et al. 2016). Mutations in the SOD1 gene results in 
conformational instability of the protein, which leads to the formation of 
large intracellular protein aggregates that contribute to motor neuron death 
(Bruijn et al. 1998) (Figure 1.2).  
 
Figure 1.2 Cu-Zn superoxide dismutase-1 (SOD1) in amyotrophic lateral sclerosis 
(ALS). In normal conditions, the SOD1 gene encodes Cu-Zn superoxide dismutase-1 
(SOD1) subunit, which when bound with copper and zinc forms a SOD1 homodimer. The 
dimeric form of SOD1 acts as an antioxidant metabolising cytotoxic radicals. Mutations 
in the SOD1 gene results in unstable monomers resulting in large intracellular protein 
aggregates, which lead to motor neuron death causing ALS. Figure adapted from  














(eg: G93A)  
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Some 130 mutations (such as G93A, G37R, and G85R) occur in the SOD1 
gene (AL-Chalabi et al. 2017), among which the G93A missense mutation 
is the most studied. The G93A mutation results in the substitution of the 
glycine residue at position 93 by an alanine residue in the SOD1 subunit 
(Kaur et al. 2016). Following the discovery of this mutation in ALS, a 
number of rodent models of ALS overexpressing human mutant SOD1 
(mSOD1) have been developed that resembles human ALS (Turner and 
Talbot 2008). However, the deletion of SOD1 gene failed to develop  
ALS-like phenotype in mice (Reaume et al. 1996), which suggest that mutant 
SOD1 cause toxicity by gain of other pathogenic mechanisms rather than 
loss of enzymatic function of SOD1. The transgenic mice and rat models 
have been important tools to further understand early and late 
pathophysiological mechanisms associated with mSOD1 and to evaluate 
potential therapeutic strategies in ALS (McGoldrick et al. 2013). This 
chapter will now discuss insights into ALS pathogenesis obtained from 
studies of mSOD1 transgenic mice. 
1.1.2.2 Cell and non-cell autonomous mechanisms  
Study of the mSOD1 mouse model reveals a number of cell and non-cell 
autonomous mechanisms that are involved in the pathophysiology of ALS. 
Cell autonomous mechanisms include changes within motor neurons such as 
axonal transport defects, mitochondrial dysfunction, increased endoplasmic 
7  
reticulum stress, glutamate toxicity and caspase activation, abnormal RNA 
metabolism and impaired proteostasis (Soo et al. 2015, Mathis et al. 2017). 
Non-cell autonomous mechanisms include neuroinflammation mediated by 
microglia and astrocytes (Hooten et al. 2015). Overall, both cell and non-cell 
autonomous mechanisms contribute to motor neuron death in ALS. Since 
chapter two aims to study various aspects of microglia in ALS, the latter 
sections in this chapter will be focused on microglia-mediated 
neuroinflammation in ALS. 
Despite the above and other knowledge in disease mechanisms leading to 
ALS, the primary factors that trigger ALS remain unknown. Findings from 
studies in mSOD1 mice suggest that mSOD1 in motor neurons initiate toxic 
actions, which in combination with non-neuronal cells also possessing 
mSOD1, accelerates motor neuron death and disease progression. Initially, 
two studies failed to demonstrate ALS in transgenic mice such as SOD1G37R, 
SOD1G93A, SOD1G85R specifically expressing mSOD1 in neurons 
(Pramatarova et al. 2001, Lino et al. 2002). In contrast, in a third study, 
SOD1G93A transgenic mice overexpressing mSOD1 selectively in neurons 
developed ALS (Jaarsma et al. 2008). In another study, disease onset in 
chimeric SOD1G37R mice was accelerated when mSOD1 was present in cells 
other than motor neuron cells (Yamanaka et al. 2008). Conversely, the 
presence of wild-type non-neuronal cells substantially delayed disease onset 
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in chimeric SOD1G37R and SOD1G85R mice (Clement et al. 2003, Yamanaka 
et al. 2008). Similarly, in transgenic SOD1G93A mice, wild-type microglia 
slowed motor neuron loss and prolonged disease duration and survival 
compared to mice possessing mSOD1 expressed microglia (Beers et al. 
2006). Together, these findings clarify that the presence of mSOD1 promotes 
motor neuron loss by both cell and non-cell autonomous processes in 
transgenic mSOD1 mice.  
Following motor neuron death, mSOD1 aggregates are released into the 
extracellular environment to provide a positive feedback loop to further 
induce motor neuron death (Brundin et al. 2010). These extracellular 
mSOD1 aggregates are not directly toxic to motor neurons, but rather 
activate microglia, which then mediate neurotoxicity. SOD1 aggregates in 
the extracellular space are taken up by neighbouring cells via 
micropinocytosis or in association with vesicles (Zeineddine and Yerbury 
2015; Silverman et al. 2016). In vitro studies have demonstrated that the 
extracellular mSOD1 cause detectable injury to motor neurons when  
co-cultured with microglia, but had no effect on motor neurons in the 




1.1.3 Dual role of activated microglia in ALS 
Microglia are the resident macrophages of the central nervous system (CNS). 
Microglia are a highly dynamic population surveying the microenvironment 
with extremely motile processes, which take part in the innate immune 
response (Nimmerjahn et al. 2005, Cherry et al. 2014). In response to 
damage or injury, microglia become activated, inducing their migration to 
the site of injury, proliferation and causing the release of damage-associated 
molecular patterns, cytokines, chemokines and reactive nitrogen and oxygen 
species to promote neuroinflammation (Becher et al. 2017). It is generally 
considered that activated microglia exhibit two different phenotypes in ALS, 
M1 and M2 phenotypes (Parisi et al. 2016, Geloso et al. 2017), although this 
concept remains controversial and is considered an over-simplification 
(Ransohoff 2016). In ALS, microglia possess early protective M2 phenotype 
characterised by small cell bodies with shorter and simple processes, and late 
neurotoxic M1 phenotype exhibiting large cell bodies with short and 
extensively branched processes (Ohgomori et al. 2016).  
The dual role of ALS-related microglia has been demonstrated when 
mSOD1 expressed M2 microglia isolated from ALS mice at disease onset 
protected co-cultured motor neurons. On the other hand, mSOD1 expressed 
M1 microglia isolated from ALS mice at disease end-stage damaged  
co-cultured motor neurons (Liao et al. 2012). The activation of microglia 
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(microgliosis) and subsequent neuroinflammation is a major cause of fALS 
(Hooten et al. 2015), although it remains unknown if a similar mechanism is 
a major cause of sALS In humans, increased microgliosis has been 
demonstrated in the spinal cords of specimens from ALS patients (Yiangou 
et al. 2006). Microgliosis occurs specifically with motor neuron injury in the 
motor cortex, along the corticospinal tract, and in the ventral horn of the 
spinal cord (Philips and Robberecht 2011).  
During early phases of disease, M2 phenotype possess a protective response 
against signals triggered by motor neuron damage. M2 phenotype release 
anti-inflammatory cytokines and neurotrophic factors including interleukin 
(IL)-4, IL-10, IL-13, and insulin-like growth factor-1 to promote motor 
neuron survival (Du et al. 2016; Tang and Le 2016). Consistently, in 
SOD1G93A and SOD1G37R mice, overexpression of anti-inflammatory IL-10 
have been demonstrated at the pre-onset phase of disease progression 
(Gravel et al. 2016). An anti-inflammatory cytokine, IL-4, has also been 
shown to suppress the release of reactive oxygen species and nitric oxide, 
and protected co-cultured primary motor neurons against  
microglia-mediated motor neuron damage (Zhao et al. 2006).  
Despite, the actual processes that transform protective microglia into a toxic 
form is still unknown, it is believed that the prolonged period of microglial 
activation will transform protective M2 phenotype into deleterious M1 
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phenotype. M1 phenotypes promote the release of pro-inflammatory factors 
such as IL-1α, IL-1β, IL-6, IL-12, IL-23 and tumor necrosis factor (TNF)-α, 
chemokines, prostaglandin E2, chemokine (C-C motif) ligand 2, ROS and 
inducible nitric oxide synthase to proliferate motor neuron death (Hooten  
et al. 2015, Du et al. 2016, Geloso et al. 2017). Furthermore, the death of 
motor neurons results in the release of mSOD1 to provide a positive 
feedback loop to further induce microglia-mediated motor neuron death 
(section 1.1.2.2) (Figure 1.3).  
  
Figure 1.3 Dual role of microglia in amyotrophic lateral sclerosis (ALS). Findings 
from numerous studies suggest that mutant SOD1 (mSOD1) in neuron initiate toxic 
actions which in combination with microglia possessing mSOD1 accelerates motor 
neuron death. During the initial stages, M2 phenotype possesses protective response by 
releasing anti-inflammatory cytokines in response to signals triggered by motor neuron 
damage. Then, the prolonged period of microglial stimulation will transform protective 
M2 phenotype into deleterious M1 phenotype and promotes release of pro-inflammatory 
factors which accelerate motor neuron death. Furthermore, the death of motor neurons 
results in mSOD1 release to provide a positive feedback loop to further induce  

















Thus, the dual role of microglia in ALS is well established. The modulation 
of microglial function serves as a promising therapeutic strategy. However 
detailed understanding of molecular mechanisms involved in microglial 
activation and identification of molecular players that trigger microglial 
activation is necessary. The P2X7 receptor, present on the surface of 
microglia and which modulates microglial activation and proliferation is one 
such molecular player (Monif et al. 2010). 
1.2 The P2X7 receptor 
The P2X7 receptor is a purinergic receptor that belongs to the P2X family 
and is encoded by the P2RX7 gene (Coddou et al. 2011). The major 
contribution of the P2X7 receptor in inflammation makes this receptor a 
promising target in many inflammatory diseases including inflammation in 
neurodegenerative diseases (Burnstock 2016, Adinolfi et al. 2018). 
1.2.1 The P2X7 receptor structure 
The P2X7 receptor is a trimeric ion channel that allows the rapid influx of 
sodium and calcium ions and efflux of potassium ions following activation 
by extracellular adenosine 5’-triphosphate (ATP) (Sluyter 2017a). Each 
P2X7 subunit is made up of 595 amino acid residues consisting a large 
extracellular loop, two transmembrane (TM) domains, and cytoplasmic 
amino- and carboxy-terminal tails. The unique feature of this receptor is the 
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presence of long cytoplasmic carboxy-terminal tail which is 239 amino acid 
long (Sluyter 2017a). Based initially on the crystal structure of the zebrafish 
P2X4 receptor (Kawate et al. 2009), the P2X7 subunit is often compared to 
the shape of a dolphin. In this comparision, the two transmembrane domains 
represent the dolphin fluke and the different segments of the large 
extracellular loop represent the head, flippers and dorsal fin of the dolphin 
(Di Virgilio et al. 2017) (Figure 1.4). This extracellular loop contains five 
cysteine amino acid pairs to form five disulphide bridges (Lenertz  
et al. 2010) (Figure 1.4).  
 
Figure 1.4 The P2X7 receptor subunit. (A) Each P2X7 subunit is made up of 595 amino 
acid residues consisting of a large extracellular loop, two transmembrane domains (TM1 
and TM2), and cytoplasmic amino- and carboxy-terminal. Three P2X7 subunits 
oligomerise to form the P2X7 receptor (not shown) (B) The structure of P2X7 subunit is 
often compared to the shape of a dolphin, where the two transmembrane domains 
represent the dolphin fluke and the different segments of the large extracellular loop 
represent head, flippers and dorsal fin of the dolphin body. Figures adapted from  











The crystal structures of the human P2X3 receptor (Mansoor et al. 2016), 
zebrafish P2X4 receptor (Hattori and Gouaux 2012) and panda P2X7 
receptor (Karasawa and Kawate 2016) provide insight on the agonist and 
antagonist binding sites of the P2X7 receptor. Computer modelling indicates 
that the binding site for ATP is located at the intersection of the extracellular 
loops of two neighboring subunits (Jiang et al. 2013). The P2X7 receptor is 
different from other P2X receptors, requiring relatively high concentrations 
of extracellular ATP for activation, with a half maximal effective 
concentration (EC50) of 100-300 µM (Jarvis and Khakh 2009). The reason 
for this low affinity for ATP is explained by sequence differences and the 
tertiary structure of the entrance of the ATP-binding pocket. In the P2X7 
receptor, the ATP binding pockets are narrow in shape and lack positively 
charged amino acid residues at its entrance, making it difficult for 
hydrophilic compounds such as ATP to enter and bind (Di Virgilio et al. 
2017). Upon entry of ATP into this pocket, phosphate groups of ATP bind 
several charged amino acid residues (Lys64, Lys66, Lys193, Arg294, and 
Lys311), whilst the adenine moiety of ATP interacts with a threonine residue 
(Thr189) present at the bottom of the binding pocket (Di Virgilio et al. 2017). 
The crystal structure of the panda P2X7 receptor revealed an  
antagonist-binding pocket site distinct from the ATP-binding pocket, but 
also located in a groove formed between two neighbouring subunits. This 
study identified that five structurally different P2X7 receptor antagonists 
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(including JNJ-47965567 which is used in this thesis) bound this pocket. 
Upon activation by ATP, the P2X7 receptor undergoes conformational 
changes, which narrows this inter-subunit space and drug-binding pocket. 
Binding of allosteric antagonists in the drug-binding pocket prevents the 
constriction of inter-subunit space and modulates ATP-binding site, thereby 
preventing P2X7 receptor activation (Karasawa and Kawate 2016).  
The P2X7 receptor, in the absence of extracellular ATP, can mediate 
phagocytosis of dying or dead cells (see Section 1.2.5). Notably, specific 
P2X7 antagonists fail to impair P2X7 receptor-mediated phagocytosis (Ou 
et al. 2018). This indicates that if the central role of the P2X7 receptor in a 
given mechanism or disease state is related to its phagocytic function rather 
than its channel function, then the use of specific P2X7 antagonists may fail 
to reveal a role for this receptor or establish its value as a therapeutic target 
including in animal studies. 
1.2.2 Macropore formation by the P2X7 receptor  
A typical functional feature of the P2X7 receptor activation is opening of a 
pore which allows uptake of large molecules up to ~900 Da (Yan et al. 2010). 
The macropore allows the transport of large organic cations including 
ethidium+, N-methyl-D-glucamine+ and YO-PRO-12+ across the plasma 
membrane (Jarvis and Khakh 2009). The long carboxy-terminus of the P2X7 
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receptor subunit is needed to generate the macropore. Initially, it was shown 
that truncation of the carboxy-terminal of the rat P2X7 receptor at amino 
acid residue 418 abolished macropore formation (Surprenant et al. 1996). 
Further studies in which the carboxyl-terminal tail of the P2X7 receptor was 
modified or truncated confirmed the importance of this region to macropore 
formation (Smart et al. 2003, Sun et al. 2013, Mansoor et al. 2016). 
Moreover, membrane cholesterol has been shown to modulate P2X7 
receptor macropore formation via the carboxyl-terminal tail. The P2X7 
receptor is associated with cholesterol rafts in the plasma membrane and its 
carboxy-terminal tail is palmitoylated (Gonnord et al. 2009). During 
macropore formation, this palmitoylated carboxy-terminal tail is inserted 
into the plasma membrane, thus preventing cholesterol interaction with the 
P2X7 receptor and allows the formation of macropore (Karasawa et al. 
2017).  
1.2.3 Distribution of the P2X7 receptor 
P2X7 receptors are distributed widely in blood and the brain. Blood cells 
such as monocytes, macrophages, dendritic cells, lymphocytes and 
erythrocytes express P2X7 receptors (Di Virgilio et al. 2001). In the brain, 
the P2X7 receptor is expressed abundantly on microglia as well as on 
astrocytes, oligodendrocytes and Schwann cells (Skaper et al. 2006, 
Sperlágh et al. 2006). Of note, a number of glial cell lines have been used to 
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understand the function of P2X7 receptors in these cells. Our laboratory for 
example, has previously used murine EOC13 microglial cell line to 
demonstrate that P2X7 receptor activation on these cells can mediate 
production of reactive oxygen and nitrogen species, as well as the death of 
these cells (Bartlett et al. 2013). Thus, such cell lines remain useful tools to 
study P2X7 receptors. 
The presence of P2X7 receptors on neuronal cells is controversial. The P2X7 
receptor has been identified in the cerebral cortex, hippocampus, brainstem, 
spinal cord and at neuromuscular junctions (Weisman et al. 2012). Several 
reports have also established the presence of P2X7 receptor on cultured 
motor neurons (Gandelman et al. 2013, Franco et al. 2013). Surprisingly, 
some reports have shown that P2X7 receptor antibodies stain hippocampal 
structures within P2X7 receptor knock out mice (Sim et al. 2004), and the 
presence of functional P2X7 receptor in the synaptosomes of those mice 
(Sánchez-Nogueiro et al. 2005, Marín-García et al. 2008) create doubts on 
the presence of neuronal P2X7 receptors. These results however may be due 
to the presence of functional splice variants, which may have escaped 
deletion in these mice (Illes et al. 2017). Thus, further research is required 
to confirm the existence of neuronal P2X7 receptors. 
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1.2.4 The P2X7 receptor as a cytotoxic receptor 
One of the intriguing features of the P2X7 receptor is its ability to mediate 
ATP-induced cell death. P2X7-mediated cell death depends on cell type, 
agonist concentration and duration of activation (Di Virgilio et al. 1989). 
The P2X7 receptor can mediate either necrosis or apoptosis, and is 
associated with rapid blebbing of the plasma membrane (Wilson et al. 2002, 
Savio et al. 2018). Previously, P2X7-mediated cell death has been described 
in lymphocytes (Taylor et al. 2008), macrophages (Liu et al. 2010), leukemic 
cells (Salaro et al. 2016), mesengial cell (Schulze-Lohoff et al. 1998) and in 
microglia (Ferrari et al. 1997, He et al. 2017).   
1.2.5 The P2X7 receptor as a phagocytic receptor 
Another intriguing feature of the P2X7 receptor is that, in the absence of 
extracellular ATP, this receptor can serve as a phagocytic receptor of dying 
or dead cells potentially promoting inflammation and immunity. Studies 
have shown that P2X7 receptors on human monocytes or monocyte-derived 
macrophages, murine macrophages or astrocytes, or HEK-293 
heterologously expressing P2X7 receptors possess phagocytic activity (Gu 
et al. 2010, Gu et al. 2011, Yamamoto et al. 2013, Perez-Flores et al. 2016). 
Moreover, these studies demonstrated P2X7 receptors, in the absence of 
extracellular ATP, can mediate the phagocytosis of non-opsonised beads, 
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heat-killed bacteria, and apoptotic lymphocytes or neuronal cells. In contrast, 
the presence of extracellular ATP can prevent this process both in vitro and 
in vivo (Gu et al. 2010). Serum glycoproteins can also inhibit P2X7  
receptor-mediated phagocytosis of apoptotic lymphocytes and neuronal cells 
by human monocyte-derived macrophages, whereas cerebrospinal fluid in 
the CNS (which is devoid of glycoproteins) do not affect this process (Gu  
et al. 2012). Collectively, these studies suggest that P2X7 receptor-mediated 
phagocytosis could play (undefined) roles in preventing or promoting 
neuroinflammatory conditions, including ALS. 
1.3 The P2X7 receptor in ALS 
Purinergic signalling is the combined action of extracellular nucleosides and 
nucleotides, purinergic receptors and extracellular ectoATPases (Volonte  
et al. 2011). This signalling pathway plays an important role in 
neurodegeneration, neuroprotection and neuroregeneration in the CNS 
(Burnstock 2016), including neurological diseases with motor symptoms 
(Oliveira-Giacomelli et al. 2018). Moreover, purinergic signalling molecules 
and pathways, especially the ATP-P2X7 receptor signalling axis is important 
in the development of ALS (Volonte et al. 2016). The remainder of this 
chapter will review the contribution of P2X7 receptors in ALS. 
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1.3.1 The P2X7 receptor on microglia 
The P2X7 receptor on microglia is thought to drive the progression of ALS. 
P2X7 receptor overexpression is sufficient to drive microglial activation in 
rat primary hippocampal cultures in the absence of pathological conditions 
(Monif et al. 2009). Moreover, P2X7 receptor activation promotes 
microglial stimulation, proliferation, and release of proinflammatory 
cytokines such as TNF-α and IL-1β, causing neuroinflammation and cell 
death (Volonte et al. 2012). In spinal cords from ALS patients, the 
upregulation of P2X7 receptor and microgliosis have been reported 
(Yiangou et al. 2006), supporting the concept that P2X7 receptor may cause 
neurodegeneration through microglial activation in ALS in humans. The 
P2X7 receptor is also upregulated in the spinal cord of SOD1G93A rats 
(Casanovas et al. 2008) and in microglia from SOD1G93A mice (D'Ambrosi 
et al. 2009). Moreover, this latter study showed that activation of the P2X7 
receptor on mSOD1 microglia caused an increase in TNF-α and 
cyclooxygenase-2, exerting toxic effects on neuronal NSC-34 and SH-SY5Y 
cell lines (D'Ambrosi et al. 2009).  
P2X7 receptor activation on microglia can also contribute to oxidative stress 
in ALS. (Cozzolino et al. 2012). In vitro studies demonstrated P2X7 receptor 
activation in microglia induced co-cultured neuronal cell death via 
production of reactive oxygen and nitrogen species (Skaper et al. 2006, 
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D’Ambrosi et al. 2009), whilst P2X7 receptor activation on SOD1G93A 
microglia by 2’-3’-O-(benzoyl-benzoyl) ATP increases the assembly and 
activity of NADPH oxidase-2 (Apolloni et al. 2013b). NADPH oxidase-2 is 
an enzyme responsible for the production of intracellular and extracellular 
reactive oxygen species, which can destroy motor neurons (Block 2008).  
Finally, a role for P2X7 receptor activation of microglia in ALS is indirectly 
supported by activities of ectoATPases. EctoATPases are the enzymes which 
degrade nucleoside triphosphates into nucleoside diphosphates, 
monophosphates, nucleosides and other derivatives (Sebastian-Serrano et al. 
2014), which in turn regulates the potential activities of purinergic receptors 
(Yegutkin 2008). The main ectoATPases include ectonucleotide  
triphospho-diphosphohydrolase-1 (CD39), ectonucleotide pyrophosphatase 
phosphodiesterases, tissue non-specific alkaline phosphatase 
phosphomonoesterase and ecto-5'-nucleotidase (CD73) (Sebastian-Serrano 
et al. 2014). CD39 is abundantly expressed on leukocytes and smooth muscle 
cells (Yegutkin 2014). In the CNS, CD39 is expressed only on microglia but 
not on astrocytes and neurons (Braun et al. 2000). Data indicates an 
important role for the down-regulation of CD39 in ALS. Microglia from 
SOD1G93A mice have a reduced extracellular ATP hydrolyzing activity 
compared to microglia from wild-type mice (D’Ambrosi et al. 2009). 
Consistent with this observation, CD39 mRNA expression is reduced in 
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microglia from the spinal cords of SOD1G93A mice compared to wild-type 
mice (Butovsky et al. 2015). Thus, reduced microglial CD39 expression in 
ALS may lead to higher extracellular ATP concentrations and increased 
P2X7 receptor activation to promote disease. 
1.3.2 The P2X7 receptor on astrocytes 
P2X7 receptor activation on astrocytes can promote ALS. Astrocytes, in 
addition to microglia, produce proinflammatory cytokines and reactive 
oxygen and nitrogen species (Barbeito et al. 2004). Additionally, activated 
microglia can secrete cytokines to induce so-called A1 astrocytes, which are 
abundant in the CNS of ALS patients and can induce the death of neurons 
(Liddelow et al. 2017). Notably, SOD1G93A mutant astrocytes play important 
roles in both neuroinflammation and motor neuron death in ALS (Nagai  
et al. 2007). Moreover, P2X7 receptor activation on SOD1G93A mutant 
astrocytes causes the production of neurotoxic factors and subsequent death 
of motor neurons (Gandelman et al. 2010). 
1.3.3 The P2X7 receptor mediates disease progression in ALS mice 
The role of the P2X7 receptor in the progression of ALS has been examined 
in three studies using the P2X7 antagonist Brilliant Blue G (BBG) in 
SOD1G93A mice. In the first study, treatment of SOD1G93A mice with  
45.5 mg/kg BBG intraperitoneally (i.p) after onset (first sign or symptom) 
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improved motor coordination and weight loss. The delay in weight loss was 
also greater in male than female mice (Cervetto et al. 2013). In the second 
study, administration of 50 mg/kg BBG (i.p) in SOD1G93A mice from late 
pre-onset improved motor coordination whereas administration of  
250 mg/kg BBG (i.p) from late pre-onset delayed disease onset, improved 
motor coordination and clinical scores in SOD1G93A mice. BBG treatment 
(250 mg/kg) from late pre-onset also reduced motor neuron loss, 
microgliosis and pro-inflammatory markers. The same doses of BBG 
however had no effect when administered from asymptomatic and pre-onset 
stages (Apolloni et al. 2014). Finally, in the third study conducted in our 
laboratory, administration of 45.5 mg/kg BBG (i.p) at late pre-onset delayed 
weight loss and extended survival in female SOD1G93A mice (Bartlett et al. 
2017). In contrast to the studies with BBG, genetic ablation of the P2X7 
receptor in SOD1G93A mice observed anticipated and worsened disease onset; 
increased microgliosis, astrogliosis, motor neuron loss, activation of 
NADPH oxidase 2 and stimulation of the downstream signalling pathway 
(Apolloni et al. 2013a). These findings together with the positive outcomes 
demonstrated by P2X7 receptor blockade with BBG treatment at different 
stages of disease, suggest a complex role for the P2X7 receptor in ALS. 
Moreover, these studies suggest that P2X7 receptors possess a 
neuroprotective role, at least during the pre-symptomatic stages of the 
disease, which may be related to beneficial (but unknown) events 
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downstream of P2X7 receptor activation and/or via scavenging of dead cells 
in the absence of extracellular ATP. On the other hand, the therapeutic 
potential of the P2X7 receptor may be enhanced if treatment is commenced 
in the initial symptomatic stages of disease. If we consider the detrimental 
effect of P2X7 receptor may have on microglial activation, the dual role of 
microglia also supports a neuroprotective or scavenging role of P2X7 
receptor in the asymptomatic stages, and a neurodegenerative role in the 
symptomatic stages of ALS.  
Despite BBG supporting a role for the P2X7 receptor in ALS progression, 
the effect of BBG was small. The limited effect of BBG in SOD1G93A mice 
may be because BBG has recently been reported as a relatively poor  
CNS-penetrant P2X7 antagonist. The administration of BBG at 50 mg/kg in 
rats detected low concentrations of BBG in the brain (~13-22 ng/mL) 
compared to plasma (~2000 ng/mL) (Bhattacharya and Biber 2016). Since 
BBG is a blue color dye, the examination of BBG colour either 
macroscopically or microscopically have also indicated the poor  
CNS-penetration of BBG with extensive BBG colouration in peripheral 
tissues (including skin, liver and spleen) but not in the brains or spinal cords 
of ALS mice treated with BBG (Sluyter et al. 2017b). Thus, the role and 
therapeutic potential of the P2X7 receptor in ALS could be demonstrated 
using CNS-penetrant P2X7 antagonists such as JNJ-47965567 
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(Bhattacharya et al. 2013). JNJ-47965567 has been previously demonstrated 
therapeutic efficacy in rodent models of temporal lobe  
epilepsy (Jimenez-Pacheco et al. 2016) and in neuropathic pain 
(Bhattacharya et al. 2013) 
1.4 Overview 
Despite the limited effect of BBG in SOD1 mice, a role for the P2X7 receptor 
in ALS progression can be proposed. It is hypothesized that mSOD1 within 
motor neurons initiate motor neuron damage. The death of motor neurons 
promotes extensive release of ATP which aggravates the activation of P2X7 
receptor present on the surface of microglia and astrocytes to release 
cytotoxic factors which, in turn accelerate motor neuron death. In parallel, 
the presence of low level of CD39 on microglial surface maintains the high 
extracellular concentration of ATP to activate P2X7 receptors (Figure 1.5). 
1.5 Summary and research aims 
ALS is a complex, progressive and fatal motor neuron disease. Despite 
having tremendous knowledge in disease mechanisms leading to ALS, the 
challenge remains to identify potential therapeutic targets in ALS. Among 
different factors contributing to the progression of ALS, the involvement of 
ATP-P2X7 signalling axis plays a role in this disease through the activation 




Figure 1.5 Proposed mechanism for P2X7 receptor-mediated progression of motor 
neuron death in amyotrophic lateral sclerosis (ALS). It is hypothesized that mutant 
SOD1 (mSOD1) within motor neurons initiate motor neuron damage. The death of motor 
neurons promotes extensive release of ATP which aggravates the activation of P2X7 
receptor present on the surface of the microglia and astrocytes to release cytotoxic factors 
and accelerate motor neuron death. The presence of low level of CD39 on the microglial 
surface maintains a high extracellular concentration of ATP to activate P2X7 receptors. 
understand the roles of the ATP-P2X7 signalling axis in ALS, cellular 
models that closely resembles ALS-associated models would be beneficial 
to establish. Furthermore, the use of CNS-penetrant P2X7 antagonists might 
further establish the role of the P2X7 receptor in ALS progression in vivo. 
Thus, this study aims to investigate the P2X7 receptor and CD39 on murine 
EOC13 microglia to determine if it may serve as a suitable in vitro model of 
these molecules on microglia in ALS. Additionally, this study also seeks to 
determine if CNS-penetrant P2X7 antagonists JNJ-47965567 ameliorates 
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2.1.1 Contribution of microglia in amyotrophic lateral sclerosis 
Amyotrophic lateral sclerosis (ALS) is a complex, progressive and fatal 
motor neuron disease (Boillee et al. 2006). Microglia, the resident 
macrophages of the central nervous system (CNS), play a crucial role in 
neuroinflammation to promote motor neuron loss in ALS (Hooten et al. 
2015). Increased microgliosis has been observed in spinal cords of ALS 
patients (Yiangou et al. 2006). In ALS, the dual role of microglia is well 
established. In ALS mice, mutant SOD1 (mSOD1) expressing M2 microglia 
isolated at disease onset protected co-cultured motor neurons, whilst mSOD1 
expressing M1 microglia isolated at disease end-stage damaged co-cultured 
motor neurons (Liao et al. 2012). Thus, the modulation of microglial 
function serves as a promising therapeutic strategy in ALS. 
2.1.2 Role of ATP-P2X7 mediated microglial activation in ALS 
progression 
The P2X7 receptor is a trimeric ion channel that allows the flow of ions 
following activation by extracellular adenosine 5’-triphosphates (ATP) 
(Sluyter 2017a). P2X7 receptor is expressed abundantly on microglia 
(Skaper et al. 2006). Our laboratory has previously demonstrated the 
presence of P2X7 receptor on EOC13 murine microglial cell line (Bartlett  
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et al. 2013). This receptor is upregulated in spinal cords from ALS patients 
and SOD1G93A rats, and in microglia from SOD1G93A mice (Yiangou et al. 
2006, Casanovas et al. 2008, D'Ambrosi et al. 2009). The ATP-P2X7 
receptor signalling axis is important in the development of ALS. P2X7 
receptor activation promotes microglial stimulation, proliferation, and 
release of proinflammatory cytokines such as tumor necrosis factor  
(TNF)-α, interleukin (IL-1β) and reactive oxygen species causing 
neuroinflammation and motor neuron death in ALS (Volonte et al. 2016).  
Ectonucleotide triphospho-diphosphohydrolase-1 (CD39) is an ectoATPase 
that degrades extracellular ATP into adenosine 5’-diphosphate and 
adenosine 5’-monophosphate (Sebastian-Serrano et al. 2014). As such, 
increased CD39 expression negatively regulates P2X7 receptor activation in 
various cell types including macrophages (Lévesque et al. 2010). Of note, 
microglia from SOD1G93A mice have reduced ectoATPase activity and 
Entpd1 mRNA expression (Entpd1 which encodes for CD39) compared to 
microglia from wild-type mice (D’Ambrosi et al. 2009, Butovsky et al. 
2015). Combined, these data indicate that CD39 expression and activity in 
microglia is down-regulated in ALS, which may contribute to increased 
P2X7 activity in these cells in this disease. Consistent with this, P2X7 
activity is increased in microglia from SOD1G93A mice compared to 
microglia from wild-type mice (D’Ambrosi et al. 2009). Thus,  
30  
ALS-associated microglia can be defined as P2X7 receptor high but CD39 
low cells. 
2.1.3 Aims 
Our group has previously shown, using flow cytometric techniques and 
immunoblotting, that the murine EOC13 microglia cell line expresses a high 
amount of functional P2X7 receptor (Bartlett et al. 2013). However, the 
presence of CD39 or ectoATPase activity on these cells remains unknown. 
Thus, this study aimed to confirm the presence of P2X7 receptor on EOC13 
cells, and to determine the relative CD39 expression and ectoATPase activity 
on these cells. These data will address whether EOC13 cells may serve as a 
potential in vitro model of these molecules on ALS-associated microglia. 
2.2 Materials and Methods 
2.2.1 Reagents 
Dulbecco’s Modified Eagle’s/F12 medium (DMEM/F12), GlutaMAX, 
0.05% trypsin-ethylenediaminetetraaceticacid (EDTA), Rosewell Park 
Memorial Institute-1640 (RPMI-1640) medium,  
ammonium-chloride-potassium (ACK) lysing buffer, Dulbecco’s  
phosphate-buffered saline (PBS), 100x HaltTM protease inhibitor single-use 
cocktail, and SuperSignal West Pico Chemiluminescent Substrate were from 
31  
ThermoFisher Scientific (Waltham, MA, USA). Fetal bovine serum (FBS) 
(heat inactivated before use) was from Bovogen Biologicals (East Keilor, 
Australia). β-Mercaptoethanol, ATP, 2-(hydroxypropyl)-beta-cyclodextrin 
(β-CD) and bovine serum albumin (BSA) were from Sigma-Aldrich  
(St. Louis, MO, USA).  Phenylmethylsulfonylfluoride (PMSF), 
dithiothreitol (DTT), ethidium bromide, Triton X-100 and potassium 
dihydrogen phosphate (KH2PO4) were from Amresco (Solon, OH, USA). 
Agarose was from Bioline (London, UK). Protease inhibitor cocktail tablets 
(complete, Mini, EDTA-free) were from Roche Diagnostics (Mannheim, 
Germany). Precision Plus protein dual colour standards were from Bio-Rad 
(Hercules, CA, USA). JNJ-47965567 was from Tocris Bioscience (Ellisville, 
MO, USA). All other reagent grade chemicals and salts were from  
Sigma-Aldrich or Amresco. Recipes for general solutions are listed in 
Appendix A.  
 2.2.2 Antibodies 
Rat anti-murine P2X7 monoclonal antibody (mAb) (clone 1F11), rat IgG2b 
isotype control mAb (clone RTK4530), phycoerythrin (PE)-conjugated rat 
anti-mouse CD39 mAb (clone Duha59), and PE-conjugated rat IgG2a 
isotype control mAb (clone RTK2758) were from BioLegend (San Diego, 
CA, USA). Allophycocyanin (APC)-conjugated donkey anti-rat IgG 
antibody (Ab) was from eBioscience (San Diego, CA, USA). Purified rat 
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anti-mouse CD16/CD32 mAb (clone 2.4G2) (Fc Block) was from BD 
Bioscience (San Diego, CA, USA). Rabbit anti-mouse CD39 Ab (ab128666) 
was from Abcam (Cambridge, UK). Rabbit anti-eukaryotic actin Ab 
(A2066) was from Sigma-Aldrich (St. Louis, MO, USA).  
Peroxidase-conjugated goat anti-rabbit IgG Ab was from Rockland 
Immunochemicals (Gilbertsville, PA, USA). 
2.2.3 Cell lines 
2.2.3.1 EOC13 microglia 
The murine EOC13 microglial and murine LADMAC lymphoblastic cell 
lines were obtained from the American Type Culture Collection (ATCC) 
(Manassas, VA, USA) and cultured according to ATCC specifications. 
EOC13 cells were maintained in DMEM/F12 supplemented with 10% FBS, 
2 mM GlutaMAX (complete culture medium) and 20% LADMAC 
conditioned medium (Appendix A) at 37oC and 95% air/5% CO2. When 90% 
confluent, cells were harvested with 5 ml 0.05% trypsin-EDTA at 37oC and 
95% air/5% CO2 for 5 min, followed by the addition of 10 ml of complete 
culture medium. Any remaining adherent cells were removed by mechanical 
scrapping and centrifuged for 5 min at 300 x g. Cells were sub-passaged 1:3 
every 3-4 days. 
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2.2.3.2 RAW 264.7 macrophages 
The murine RAW 264.7 macrophage cell line was also originally obtained 
from ATCC and cultured according to ATCC specifications. RAW 264.7 
macrophages were maintained in complete culture medium at 37oC and  
95% air/ 5% CO2. When 90% confluent, cells were harvested by mechanical 
scrapping and centrifuged for 5 min at 300 x g. Cells were sub-passaged 1:10 
every 3-4 days.  
2.2.4 Spleen cells 
A C57BL/6J mouse spleen (Australian BioResources, Moss Vale, Australia) 
was kindly provided by Carlee Mottley (University of Wollongong, 
Wollongong, Australia) under institutionally-approved shared animal tissue 
arrangements. The spleen was mechanically dissociated in RPMI-1640 
medium supplemented with 10% FBS. Spleen cells were then filtered 
through a 70 µm strainer (Greiner Bio-one, Kremsmünster, Austria) and 
incubated in ACK lysis buffer at room temperature for 5 min. Lastly, cells 
were washed once with PBS containing 10% FBS (PBS/10%FBS) for 5 min 
at 300 x g and resuspended in ice-cold PBS/10% FBS. 
2.2.5 RNA isolation and reverse transcription polymerase chain reaction 
RNA isolation from EOC13 cells and cDNA synthesis was carried out as 
described (Geraghty et al. 2017). Harvested EOC13 cells were washed twice 
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with PBS. Ribonucleic acid (RNA) was isolated from EOC13 cells using an 
Isolate II RNA Mini Kit (Bioline, London, UK) according to the 
manufacturer’s instructions. Isolated RNA was converted to complementary 
DNA (cDNA) using qScript cDNA Synthesis Kit (Quanta Biosciences, 
Gaithersburg, MD, USA) as per the manufacturer’s instructions and stored 
at -20oC until use. cDNA synthesis was then checked by reverse transcription 
polymerase chain reaction (RT-PCR) using primers to the housekeeping 
gene Actb (ThermoFisher Scientific, Waltham, MA, USA). PCR was run at 
95oC for 5 min followed by 35 cycles at 95oC for 30 s, 55oC for 30 s and 
72oC for 1 min and then holding at 72oC for 8 min, 35oC for 3 min and at 
4oC until samples were collected for further processing. cDNA originally 
obtained from a BALB/c mouse spleen (Bartlett et al. 2017) was used as a 
positive control, and was kindly provided by Debbie Watson (University of 
Wollongong, Wollongong, Australia). The purity and size of amplicons were 
confirmed by separating on a 1.5% agarose gel in Tris-acetate-EDTA buffer 
(40 mM Tris, 20 mM acetic acid and 1 mM EDTA) and visualised using 
ethidium bromide staining. Images of gels were collected using a Bio-Rad 
Criterion Stain Free Imager and Image Lab Software (Bio-Rad, Hercules, 
CA, USA).  
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2.2.6 Quantitative real-time polymerase chain reaction  
PCR amplification was performed as described (Geraghty et al. 2017). 
Quantitative real-time polymerase chain reaction (qPCR) of cDNA was 
conducted in triplicate and performed using TaqMan Universal Master Mix 
II (ThermoFisher Scientific, Waltham, MA, USA) according to the 
manufacturer’s instructions with primers for VIC labelled Gapdh 
(Mm99999915_m1), FAM labelled P2rx7 (Mm01199503_m1) and  
FAM-labelled Entpd1 (Mm00515447_m1) (ThermoFisher Scientific). Each 
qPCR was run at 50°C for 2 min, followed by 95 °C for 10 min and,  
40 cycles at 95°C for 15 s and 60°C for 1 min using a Quant Studio 5 Real-
Time PCR (ThermoFisher Scientific). Relative gene expression in each 
sample was normalised to the housekeeping gene Gapdh and analysis was 
conducted using Quanta Studio Design and Analysis Software 
(ThermoFisher Scientific). Relative gene expression in EOC13 cells is 
presented relative to the corresponding gene in the BALB/c spleen. 
2.2.7 Cell-surface P2X7 receptor expression by flow cytometry  
Immunostaining of cell-surface P2X7 receptor was performed as described 
(Bartlett et al. 2013). Harvested EOC13 cells were washed twice with 
PBS/10% FBS. Cells (1x106 cells/200 µL/tube) were incubated with either 
anti-P2X7 receptor or isotype control (rat IgG2b) mAb (0.5 mg/ml) on ice for 
36  
30 min. Cells were then washed twice with 1 ml PBS/10% FCS (5 min at 
300 x g) and incubated with APC-conjugated anti-rat IgG mAb (0.2 mg/ml) 
on ice for 30 min protected from light. Cells were then washed once as above. 
Events were collected using a LSR II flow cytometer (BD Biosciences) using 
a 660/20 band-pass filter for APC. Relative expression, determined as mean 
fluorescence intensity (MFI), and the percentage of P2X7 receptor positive 
cells were determined using FlowJo Software version 8.7.1 (Tree Star, 
Ashland, OR, USA). 
2.2.8 P2X7 receptor activity 
The activity of the P2X7 receptor on EOC13 cells was assessed using a 
fixed-time ethidium+ uptake assay as described (Bartlett et al. 2013, Sluyter 
and Vine 2016). Cells were washed three times in either sodium chloride 
(NaCl) medium (140 mM NaCl, 5 mM NaOH, 5 mM KCl, 10 mM HEPES, 
0.1% BSA and 5 mM glucose, pH 7.4) or physiological medium (147mM 
NaCl, 2 mM KCl, 2mM CaCl2.2H2O, 1 mM MgCl2, 10 mM HEPES, pH 7.4). 
Cells in either assay medium (5x105
 
cells/1ml) were incubated in the absence 
or presence of 30% β-CD or 10 µM JNJ-47965567 at 37oC for 15 min. 
Ethidium bromide (25 µM) was then added and cells incubated in the 
absence or presence of 1 mM ATP at 37oC for 5 min. The assay was 
terminated by the addition of an equal volume of ice-cold NaCl medium 
containing 20 mM magnesium chloride (MgCl2) (MgCl2 medium) followed 
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by centrifugation (5 min at 300 x g). Cells were washed once with 
corresponding assay medium and events collected using a LSR II flow 
cytometer using a 575/26 band-pass filter for ethidium+. The MFI of relative 
ethidium+ uptake was determined using FlowJo Software version 8.7.1.  
2.2.9 Cell-surface CD39 expression by flow cytometry 
Harvested EOC13, RAW 264.7 and spleen cells were washed twice with 
PBS/10%FCS (5 min at 300x g). Cells (1x105 – 1x106 cells/100 µL/tube) 
were incubated with Fc Block (0.5 mg/ml) on ice for 10 min and then with 
PE-conjugated anti-CD39 or isotype control (rat IgG2a) mAb (0.2 mg/ml) on 
ice for 15 min protected from light. Cells were washed once as above  
(section 2.2.7) and events were collected using a LSR II flow cytometer 
using a 575/26 band-pass filter for PE. Relative expression was determined 
as MFI, and the percentage of CD39 positive cells were determined using 
FlowJo Software version 8.7.1. 
2.2.10 CD39 expression by Western blotting   
2.2.10.1 Cell lysates preparation 
CD39 expression in EOC13 cell lysates was examined by Western blotting 
as described (Bartlett et al. 2013). Harvested EOC13 cells were washed 
twice with PBS. EOC13 cells in ice-cold lysis buffer (1% Triton X-100,  
1 mM PMSF and complete EDTA-free protease inhibitor cocktail, 50 mM 
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BisTris, 750 mM 6-aminohexanoic acid, pH 7.0) were sheared by passing 
ten times through an 18 G needle and stored at -20oC.  
2.2.10.2 Gel electrophoresis 
For protein separation, cell lysates (section 2.2.10.1) were thawed and 
centrifuged (16,000 x g for 10 min at 4°C). The total protein concentration 
in each cell lysate supernatant was determined using the BCA Protein Assay 
Kit (ThermoFisher Scientific) as per the manufacturer’s instructions 
(Appendix B). Supernatants were mixed with 4 x SDS loading buffer 
containing 10 mM DTT (Appendix A) and incubated at 94oC for 3 min. 
Equal amounts of protein from each sample (20 µg/lane) and 10 µl Precision 
Plus protein dual colour standards were separated by sodium dodecyl 
sulphate polyacrylamide gel electrophoresis (SDS-PAGE) on  
Mini-PROTEAN TGX Precast Gels (Bio-Rad) following the manufacturer’s 
instructions. After protein separation, equal protein loading was confirmed 
by visualising stain-free gels with Stain Free Imager and Image Lab Software 
(Bio-Rad). 
2.2.10.3 Immunoblotting 
Proteins were transferred to nitrocellulose membranes (Bio-Rad). 
Membranes were blocked in Tris-buffered saline (TBS; 250 mM NaCl and 
50 mM Tris, pH 7.5) containing 0.2% Tween-20 and 5% skim milk powder 
39  
at room temperature for 2 h. Membranes were then incubated with  
anti-CD39 (1:500) and anti-β-actin (1:1000) Ab in TBS/0.2% Tween-20/5% 
skim milk overnight at 4oC. Membranes were then washed three times over 
15 min with TBS/0.2% Tween-20 and then incubated with  
peroxidase-conjugated anti-IgG (1:2000) Ab in TBS/0.2% Tween-20/5% 
skim milk at room temperature for 1 h. Membranes were then washed as 
above and visualised with SuperSignal West Pico chemiluminescent 
substrate. Protein bands were imaged using the Amersham Imager  
(GE Healthcare, Little Chalfont, Buckinghamshire, UK).  
2.2.11 EctoATPase activity 
The activity of ectoATPases on EOC13 cells was assessed by liberation of 
phosphate from ATP using the molybdite assay as described (Mansfield and 
Hughes 2014). EOC13 cells seeded in 12-well plates (2.6 x105 cells/ 
2 ml/well) were washed three times with phosphate-free buffer (20 mM 
HEPES, 120 mM NaCl, 5 mM KCl, 10 mM Glucose, 2 mM CaCl2, 1.2 mM 
MgSO4, pH 7.4) and then incubated with 100 µM ATP in phosphate free 
buffer (0.5 ml/well) at 37oC in the waterbath for 10, 20, 30 or 60 mins. 
Following each respective incubation, media aspirated and incubated with 
equal volumes of colour reagent (1% ammonium molybdite, 0.3 M H2SO4, 
4% FeSO4) at room temperature for 15 mins. The absorbance was then 
recorded at 750 nm using a POLARstar Omega plate reader (BMG Labtech, 
40  
Ortenberg, Germany). Phosphate concentration was determined relative to a 
phosphate (KH2PO4) standard curve (Appendix B) assembled in GraphPad 
Prism 5.0 (San Diego, CA, USA). Treatments were carried out in 
quadruplate and the mean phosphate concentration in nmols per treatment 
was determined.  
For the quantification of total protein in each well of the 12-well plates after 
aspirating media above, cells were lysed by 3 days incubation with NaOH 
(0.5 ml/well) at 4oC. Cell lysates were mixed with equal volume of Lowry 
reagent (2% NaOH, 0.81 M NaCO3, 1% CuSO4, 7mM Na-k Tartrate) and 
incubated with 0.03 ml Folin’s reagent (1:2 in H2O) at room temperature for 
10 min. The absorbance was recorded at 750 nm in a SPECTROStar Nano 
plate reader (BMG Labtech, Ortenberg, Germany). Total protein 
concentration was determined relative to a BSA standard curve  
(Appendix B). Estimates of protein concentration for each sample and 
standard were performed in duplicate. The phosphate concentrations (nmols) 
determined above were then normalized to the protein concentration in 
corresponding samples (µg) and presented as nmols phosphate/µg protein.  
2.2.12 Data analysis 
All analyses were performed using GraphPad Prism 5.0. Data are presented 
as mean ± standard deviation (SD). Differences between multiple treatments 
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were compared using a two-way ANOVA with a Bonferroni post-hoc test. 
Statistical differences were considered significant when P < 0.05. 
2.3 Results 
2.3.1 Quality control of cDNA from EOC13 cells  
To determine the quality of cDNA reverse transcribed from RNA of EOC13 
cells, cDNA was amplified by PCR using primers to the housekeeping gene 
Actb which codes for β-actin. cDNA from mouse splenocytes (Petry et al. 
2001) was used as a positive control (and as a reference gene for P2rx7 and 
Entpd1 gene expression below). Amplified cDNA of three individual 
EOC13 cell samples were found to yield amplicons approximately 280 base 
pairs (bp) in size, similar to cDNA of mouse splenocytes. Water, in place of 
cDNA, was used as a negative control and yielded no bands (Figure 2.1). 
2.3.2 Expression and function of the P2X7 receptor in EOC13 cells  
2.3.2.1 EOC13 cells express the P2X7 receptor 
EOC13 cells express functional P2X7 receptor (Bartlett et al. 2013), 
however the expression of P2rx7 mRNA has never been reported. To 
investigate this in EOC13 cells, qPCR of cDNA was performed using 
primers to the P2rx7 gene. P2rx7 gene expression for each sample was 












shown relative to splenic P2rx7 gene expression. The relative P2rx7 
expression in EOC13 cells was approximately 21 times that of splenic P2rx7 































Figure 2.2 EOC13 cells express relatively high amounts of P2rx7 mRNA. cDNA from 
EOC13 cells was analysed by qPCR using primers to P2rx7. P2rx7 gene expression was 
normalised to Gapdh, with P2rx7 gene expression shown relative to splenic P2rx7 gene 
expression. Data represents mean ± SD (n = 3). 
Figure 2.1 Quality control of cDNA from EOC13 cells. RNA was isolated from EOC13 
cells or mouse spleen, reverse transcribed to cDNA and amplified by PCR using primers 
to the housekeeping gene Actb. Water, in place of cDNA, was used as a negative control. 
Amplicons were separated on a 1.5% agarose gel and visualised with ethidium bromide 































Cell-surface P2X7 receptors on EOC13 cells has been demonstrated by flow 
cytometry using an anti-P2X7 mAb (clone HANO43) (Bartlett et al. 2013). 
Since then, a second anti-P2X7 mAb (clone 1F11) has become available 
(Kurashima et al. 2012). To examine the presence of cell-surface P2X7 
receptors on EOC13 cells using this newer mAb, cells were labelled with an 
isotype control or anti-P2X7 receptor (clone 1F11) mAb and analysed by 
flow cytometry. The relative binding of mAb (MFI) was determined using 
the gating strategy shown in Figure 2.3. The MFI of isotype control and 
P2X7 receptor mAb binding was 3.6 ± 0.3 and 56.3 ± 26.5 respectively, with 
a mean difference of 52.7 ± 26.2 (n = 3). Comparison of this histogram 
revealed that 86.2 ± 14.13% of EOC13 cells were positive for the P2X7 
receptor (Figure 2.3).  
 
Figure 2.3 EOC13 cells express cell-surface P2X7 receptors. EOC13 cells were 
incubated with isotype control or anti-P2X7 receptor (clone 1F11) mAb, followed by 
incubation with APC-conjugated anti-IgG Ab and then analysed by flow cytometry. (Left 
panel) Single, viable cells were first gated by forward scatter area (FSC-A) and forward 
scatter height (FSC-H), and then (middle panel) FSC-A and side scatter area (SSC-A). 
(Right panel) Histograms were used to determine anti-P2X7 receptor (red) and isotype 
control (blue) mAb binding to the surface of EOC13 cells (n = 3). Marker region (as 
shown) was used to determine the percentage of P2X7 receptor positive cells. Data is 








2.3.2.2 EOC13 cells express functional P2X7 receptors  
To confirm the presence of functional P2X7 receptors on EOC13 cells, an 
ATP-induced ethidium+ uptake assay was performed in EOC13 cells 
suspended in NaCl medium as described (Bartlett et al. 2013). EOC13 cells 
in NaCl medium were pre-incubated at 37oC for 15 min in the absence or 
presence of either β-CD or the P2X7 receptor antagonist, 10 µM  
JNJ-47965567 in β-CD (Jimenez-Pacheco et al. 2016) and then in the 
absence (basal) or presence of 1 mM ATP. Cells were gated as shown in 
Figure 2.4. Cells incubated in the absence of ATP displayed typical forward 
scatter (FSC) and side scatter (SSC) (Figure 2.4 A). However, incubation 
with ATP caused a large reduction in the FSC of cells pre-incubated in the 
absence of β-CD or JNJ-47965567, or in the presence of β-CD  
(Figure 2.4 B). Notably, this decrease in FSC by ATP was partly prevented 
by pre-incubation with JNJ-47965567 (Figure 2.4 B). This suggested that 
ATP mediated the rapid death of some EOC13 cells during the course of the 
assay. Nevertheless, cells remaining in the single, viable gate were analysed 
for ethidium+ uptake. 
In the absence of β-CD or JNJ-47965567, or presence of β-CD, ATP induced 
high amounts of ethidium+ uptake into EOC13 cells compared to 
corresponding cells incubated in the absence of ATP (basal). Pre-incubation 
with JNJ-47965567 impaired ATP-induced ethidium+ uptake by 65.72 ± 
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4.4% compared to ATP-induced ethidium uptake into cells incubated with 
β-CD and ATP (P < 0.001). Ethidium+ uptake into cells incubated in the 
absence of ATP was similar between all three treatments (Figure 2.4 C, D). 
Due to the noticeable changes in FSC above (Figure 2.4), the experiment 
was repeated using a new stock of NaCl medium to exclude the possibility 
that the initial NaCl medium was the likely cause of such changes. Changes 
in FSC, similar to above, were observed again in the new NaCl medium stock 
(data not shown). Again, similar results were found when ATP induced 
ethidium+ uptake into EOC13 cells pre-incubated in the absence of β-CD or 
JNJ-47965567, or in the presence of β-CD (Figure 2.5). Whilst  
pre-incubation with JNJ-47965567 reduced ATP-induced ethidium+ uptake 
by 59.49 ± 3.8% compared to cells incubated with β-CD and ATP  
(P < 0.001) (Figure 2.5). 
The results above (Figure 2.4 and 2.5) suggest that P2X7 receptor activity is 
causing the rapid ATP-induced death of the majority of EOC13 cells in NaCl 
medium. This medium is normally free of calcium and magnesium ions, 
which can impair P2X7 activation (Virginio et al. 1997, Yan et al. 2011). 
Thus, the experiments above were repeated using EOC13 cells in a 
physiological medium (Sluyter and Vine 2016), which contains 2mM Ca2+ 
and 1 mM Mg2+, and therefore partially limits P2X7 receptor activity and 






































Figure 2.4 EOC13 cells express functional P2X7 receptors. (A and B) EOC13 cells in 
NaCl medium were pre-incubated in the absence (control) or presence of 30% (β-CD) or 
10 µM JNJ-47965567 at 37oC for 15 min. Cells were then incubated with 25 µM 
ethidium+ in the absence (basal) or presence of 1 mM ATP for a further 5 min. Incubations 
were stopped by the addition of MgCl2 medium. Cells were gated as in Figure 2.3.  
(C) Ethidium+ uptake was determined from histograms. Data is representative of three 
independent experiments. (D) Results are shown as means ± SD (n = 3);  
*** P < 0.001 compared to JNJ-47965567 and ATP. 
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Figure 2.5 The P2X7 receptor antagonist JNJ-47965567 impairs ATP-induced 
ethidium+ uptake in EOC13 cells suspended in a second stock of NaCl medium. 
EOC13 cells in NaCl medium were pre-incubated in the absence (control) or presence of 
30% (β-CD) or 10 µM JNJ-47965567 at 37oC for 15 min. Cells were then incubated with 
25 µM ethidium+ in the absence (basal) or presence of 1 mM ATP for a further 5 min. 
Incubations were stopped by the addition of MgCl2 medium. Cells were gated as in Figure 
2.3 (data not shown). (A) Ethidium+ uptake was determined from histograms. Data is 
representative of three independent experiments. (B) Results are shown as means ± SD 
(n = 3); *** P < 0.001 compared to JNJ-47965567 and ATP. 
physiological medium was largely unchanged by incubation with ATP 
(Figure 2.6 A, B). Further, as expected ATP induced ethidium+ uptake into 
EOC13 cells pre-incubated in the presence of β-CD (P < 0.05). In contrast, 
pre-incubation with JNJ-47965567 reduced ATP-induced ethidium+ uptake 
by 99.4 ± 0.6% compared to cells incubated with β-CD and ATP (P < 0.05) 
(Figure 2.6 C, D). 
2.3.3 Expression and function of CD39 in EOC13 cells  
2.3.3.1 EOC13 cells express low amounts of CD39 
The presence of CD39 on EOC13 cells has never been reported. To 

















































































Figure 2.6 The P2X7 receptor antagonist JNJ-47965567 impairs ATP-induced 
ethidium+ uptake in EOC13 cells suspended in a physiological medium. (A and B) 
EOC13 cells in physiological medium were pre-incubated in the absence (control) or 
presence of 30% (β-CD) or 10 µM JNJ-47965567 at 37oC for 15 min. Cells were then 
incubated with 25 µM ethidium+ in the absence (basal) or presence of 1 mM ATP for a 
further 5 min. Incubations were stopped by the addition of MgCl2 medium. Cells were 
gated as in Figure 2.3. (C) Ethidium+ uptake was determined from histograms. Data is 
representative of three independent experiments. (D) Results are shown as means ± SD 
(n = 3); * P < 0.05 compared to JNJ-47965567 and ATP. 
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primers to the Entpd1 gene (encoding CD39). Entpd1 gene expression for 
each sample was normalised to the housekeeping gene Gapdh, with Entpd1 
gene expression shown relative to splenic Entpd1 gene expression. The 
relative Entpd1 expression on EOC13 cells was approximately 7% of splenic 
































Figure 2.7 EOC13 cells express relatively low amounts of Entpd1 mRNA. cDNA from 
EOC13 cells was analysed by qPCR using primers to Entpd1. Entpd1 gene expression 
was normalised to Gapdh, with Entpd1 gene expression shown relative to splenic Entpd1 
gene expression. Data represent mean ± SD (n = 3). 
mRNA expression does not always reflect protein expression (Greenbaum  
et al. 2003). Therefore, to confirm if CD39 expression is low on EOC13 
cells, cells were labelled with an isotype control or anti-CD39 mAb and 
analysed by flow cytometry. RAW 264.7 cells, which express cell-surface 
CD39 (Liao et al. 2010) were used as a positive control. The relative mAb 
binding (MFI) on EOC13 and RAW 264.7 cells was determined using the 
gating strategy shown in Figure 2.8. The MFI of isotype control and CD39 
mAb binding on EOC13 cells was 9.0 ± 2.2 and 14.2 ± 1.5 respectively, with 
a mean difference of 5.16 ± 0.7 (n = 3). Comparison of this histogram 
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revealed that 27 ± 25.35% of EOC13 cells were positive for CD39  
(Figure 2.8 A). Unexpectedly, CD39 expression on RAW 264.7 cells was 
absent. The MFI of isotype control and CD39 mAb binding on these cells 
was 7.3 ± 1.1 and 6.5 ± 1.3 respectively, with a mean difference below 0  
(n = 3) (Figure 2.8 B).  
 
Figure 2.8 EOC13 cells express low amounts of cell-surface CD39. EOC13 and RAW 
264.7 cells were incubated with PE-conjugated isotype control or anti-CD39  
(clone Duha59) mAb, and then analysed by flow cytometry. (Left and middle panels) 
Cells were gated as in Figure 2.3. (Right panels) Histograms were used to determine  
anti-CD39 (red) and isotype control (blue) mAb binding to the surface of (A) EOC13 
cells (n = 3) and (B) RAW 264.7 cells (n = 3). Marker region (as shown) was used to 
determine the percentage of CD39 positive cells on EOC13 cells. Data is representative 
of three independent experiments. 
Given the unexpected findings with the anti-CD39 mAb and RAW 264.7 
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mouse splenic leukocyte populations can express CD39 (Zhou et al. 2009). 
The relative CD39 expression (MFI) on mouse splenocytes was determined 
by using the gating strategy shown in Figure 2.9. The MFI of isotype control 
and CD39 mAb binding was 5.7 and 9.77 respectively, with a mean 
difference of 4.07 and approximately 41.2% of these cells positive for CD39 
expression (n = 1) (Figure 2.9). 
 
Figure 2.9 Mouse spleen express cell-surface CD39. Mouse splenocytes were 
incubated with PE-conjugated isotype control or anti-CD39 (clone Duha59) mAb, and 
then analysed by flow cytometry. (Left and middle panel) Cells were gated as in Figure 
2.3. (Right panel) Histograms were used to determine anti-CD39 (red) and isotype control 
(blue) mAb binding to the surface of splenocytes (n = 1). Marker region (as shown) was 
used to determine the percentage of CD39 on splenocytes. 
Finally, to confirm the absence or low expression of CD39 in EOC13 cells, 
proteins in EOC13 cell lysates were separated by SDS-PAGE and transferred 
to nitrocellulose membranes, and probed with an anti-CD39 Ab known to 
detect mouse CD39 by this method (Rao et al. 2014). An anti-β-actin Ab was 
used as a positive control. Sample loading was confirmed by the stain-free 
gel (Figure 2.10 A). Probing of the membrane with anti-β-actin Ab revealed 
the presence of a band at 43 kDa, corresponding to the molecular weight of 




















protein was observed after probing with the anti-CD39 Ab  












Figure 2.10 Absence of CD39 protein in EOC13 cell lysates. (A) EOC13 cell lysates 
and molecular weight markers (Marker) were separated by SDS-PAGE and visualised by 
stain-free imaging. (B) Separated proteins were then transferred to a nitrocellulose 
membrane and probed with either an anti-CD39 or anti-β-actin Ab. (A,B) Images are 
representative of three independent experiments. 
2.3.3.2 EOC13 cells display low ectoATPase activity 
CD39 and other ectoATPases can rapidly hydrolyse ATP, liberating nm 
amounts of phosphate (Bulavina et al. 2013, Yegutkin 2014). Therefore, to 
determine if EOC13 cells display ectoATPase activity, the capability of these 
cells to liberate phosphate from ATP (ATP hydrolysis) was assessed by the 
molybdite assay over time. Phosphate and total protein concentrations were 
determined relative to phosphate and BSA standard curves, respectively 
(Appendix B). Liberation of phosphate (ATP hydrolysis) from EOC13 cells 


























after 10 min was minimal and variable. Phosphate liberation after 20 min 
was minimal but slightly increased at 30 and 60 min. There were no 
statistically significant differences between time points (Figure 2.11). 



























Figure 2.11 EOC13 cells display low ectoATPase activity. EOC13 cells in phosphate 
free buffer were incubated with 100 µM ATP at 37oC as indicated. Supernatants were 
collected and mixed with colour reagent, and the absorbance read at 750 nm. Phosphate 
concentrations were determined using a standard phosphate curve, normalized to total 
protein present in the cells. Data is presented as mean nmols phosphate/µg protein ± SD 
(n = 4). 
2.4 Discussion 
2.4.1 Summary of results 
The current study confirms the abundant expression of functional P2X7 
receptors on the surface of murine EOC13 microglia. This study also 
revealed for the first time, negligible cell-surface expression of CD39 and 
ectoATPase activity on these cells.  
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2.4.2 EOC13 cells express high amounts of P2X7 receptors 
The current study confirms the presence of cell-surface P2X7 receptors on 
EOC13 cells. Moreover, the current study demonstrated for the first time that 
these cells express P2rx7 mRNA and demonstrate the presence of  
cell-surface P2X7 receptors on EOC13 cells, using a recently developed  
anti-P2X7 receptor mAb (clone IF11) (Kurashima et al. 2012). Of note, the 
amount of cell-surface P2X7 detected by this mAb is greater than that 
previously observed in our laboratory with an alternate mAb (HANO43) 
(Bartlett et al. 2013). Whether this difference reflects the mAb themselves, 
secondary Ab used or batch of cells remains to be determined. Regardless, 
data from the current and past studies combined reveals that P2rx7 mRNA 
(by qPCR), total P2X7 receptor protein (by Western blotting) and  
cell-surface P2X7 receptor (by confocal microscopy and flow cytometry) is 
abundant on EOC13 microglia.  
2.4.3 EOC13 cells express functional P2X7 receptor 
Consistent with the high amounts of P2X7 receptors on EOC13 cells, the 
current study confirmed the presence of robust P2X7 receptor activity on 
these cells. Similar to previous studies (Bartlett et al. 2013), 1 mM ATP 
induced ethidium+ uptake into EOC13 cells in NaCl medium. Consistent 
with P2X7 receptor reactivity, this process was reduced in physiological 
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medium which includes 2 mM Ca2+ and 1 mM Mg2+, both of which are 
known allosteric inhibitors of P2X7 receptors (Virginio et al. 1997, Yan  
et al. 2011). Moreover, the P2X7 receptor antagonist JNJ-47965567 
(Bhattacharya et al. 2013) at 10µM reduced ATP-induced ethidium+ uptake 
by approximately 66%. This inhibition is comparable to that by the P2X7 
receptor antagonist BBG at 30 µM in these cells but less than that of the 
P2X7 receptor antagonist AZ10606120 at 10 µM, which completely 
impaired 1 mM ATP-induced ethidium+ uptake in EOC13 cells (Bartlett  
et al. 2013). This difference between JNJ-47965567 and AZ10606120 is 
somewhat surprising given that JNJ-47965567 is reported to be a more 
potent inhibitor of murine P2X7 receptor than AZ10606120 (Michel et al. 
2009; Bhattacharya et al. 2013). Further studies are required to directly 
compare the pharmacological action and potency of these two antagonists in 
EOC13 cells. However, it should be noted that both compounds bind to the 
same antagonist binding pocket in the P2X7 receptor, with the binding of 
JNJ-47965567, but not AZ10606120, significantly altered by amino acid 
changes at residues F88 and F108 within this pocket (Karasawa and Kawate 
2016). Thus, it would be of interest to sequence this region of the P2rx7 gene 
in EOC13 cells, to determine if any missense mutations exist which may 
explain the reduced potency of JNJ-47965567 compared to AZ10606120 in 
these cells. 
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It is also noteworthy that pre-incubation of EOC13 cells with 30% β-CD for 
15 min did not affect the ATP-induced ethidium+ uptake compared to 
EOC13 cells pre-incubated in the absence of β-CD. Cyclodextrins are 
compounds that are widely used as drug vehicles but are also capable of 
depleting cholesterol present in the plasma membrane of cells (Al Azzam 
and Muhammad 2015). Notably, cholesterol is a negative regulator of the 
P2X7 receptor interacting directly with the transmembrane and intracellular 
domains of this receptor (Karasawa et al. 2017). Moreover, 15 min  
pre-incubation with methyl-β-CD is sufficient to increase P2X7 receptor 
activation, while 15 min pre-incubation with α-CD has no effect (Robinson 
et al. 2014). The current study indicates that short-term incubation with  
β-CD has no significant effect on P2X7 receptor activation similar to that of 
α-CD. It remains to be determined if long-term exposure to β-CD alters 
P2X7 activation. 
The assessment of P2X7 receptor activity in the current study suffered 
technical issues. ATP induced a decrease in the size (FSC) of EOC13 cells 
in NaCl medium, which resulted in a large proportion of cells moving outside 
of the viable cell gate. An effect reduced by pre-incubation with  
JNJ-47965567, suggests that this event was mediated, at least in part, by 
P2X7 receptor activation. This reduction in cell size was most likely due to 
P2X7 receptor-mediated cell death, as P2X7 receptor activation can cause 
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the death of EOC13 cells over 24 h (Bartlett et al. 2013). To circumvent this 
issue, P2X7 receptor activity in EOC13 cells was assessed in physiological 
medium, which due to the presence of Ca2+ and Mg2+ limits P2X7 receptor 
activation and thereby would also reduce the decrease in cell size (or cell 
death). The decrease in cell size (FSC) was completely prevented in EOC13 
cells suspended in physiological medium, which corresponded with 
dramatically impaired ATP-induced ethidium+ uptake compared to that in 
EOC13 cells suspended in NaCl medium. 
2.4.4 EOC13 cells display low amounts of CD39 and ectoATPase activity 
The current study revealed for the first time, that EOC13 cells express low 
amounts of Entpd1 gene expression and cell-surface CD39, whilst CD39 was 
undetectable in EOC13 cell lysates. This low amount of CD39 expression 
paralleled the low ectoATPase activity. The failure to detect CD39 by 
Western blotting may reflect technical issues as no positive control for CD39 
protein was included, although β-actin was detected in EOC13 cells by this 
method. EctoATPase activity on EOC13 cells was deemed as low, as 
comparable studies in human RT4 bladder epithelial cells resulted in the 
liberation of large nmol amounts of phosphate from 100 µM ATP over  
30 min (Mansfield and Hughes 2014) compared to low pmol amounts of 
phosphate liberated from 100 µM ATP in the current study over 10 to  
60 min. Contrary to previous observations (Liao et al. 2010), the current 
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study demonstrated the absence of cell-surface CD39 on RAW 264.7 cells. 
This result questioned the ability of the anti-CD39 mAb used to detect 
murine CD39. However, this mAb was shown to label splenocytes, which 
contains populations of CD39 positive leukocytes (Zhou et al. 2009). Thus, 
given this observation with splenocytes, and the low CD39 expression by 
qPCR and low ectoATPase activity on EOC13 cells, it indicates that the low 
cell-surface CD39 expression on EOC13 cells is accurate. The absence of  
cell-surface CD39 on RAW 264.7 cells remains unexplained but may reflect 
differences between culture conditions between laboratories. 
2.4.5 EOC13 microglia as a potential model of ALS microglia 
The current study confirms the presence of high P2X7 receptors on EOC13 
microglia as previously demonstrated by our laboratory (Bartlett et al. 2013). 
The presence of high amounts of the P2X7 receptor on EOC13 microglia 
parallels the high amounts of P2X7 receptors on microglia from SOD1 ALS 
mice (D’Ambrosi et al. 2009). The negligible amount of CD39 and 
ectoATPase activity of EOC13 cells contrasts other studies of primary 
murine microglia, which show robust CD39 and ectoATPase activity (Braun 
et al. 2000, Bulavina et al. 2013). By comparison, ectoATPase activity is 
downregulated on microglia from SOD1 ALS mice (D’Ambrosi et al. 2009). 
The expression of Entpd1 mRNA in microglia from the spinal cords of 
SOD1G93A mice is also low (Butovsky et al. 2015). Collectively, the high 
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P2X7 receptor expression and activity, and the low CD39 expression and 
ectoATPase activity on EOC13 cells parallels that of ALS-associated 
microglia. It will be of future importance to directly compare P2X7 receptor 
and CD39 expression and activity of EOC13 cells and microglia from ALS 
mice to determine if EOC13 cells are a model of ALS-associated microglia. 
2.4.6 Conclusion 
These results demonstrate that murine EOC13 microglia express a relatively 
high level of P2X7 but low level of CD39 when compared to murine spleen 
cells. This pattern reflects that of ALS-associated microglia indicating that 
EOC13 microglia may serve as a potential model to study the ATP-P2X7 
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3.1.1 The SOD1G93A mouse model of ALS 
The discovery that the superoxide dismutase-1G93A (SOD1G93A) mutation is 
associated with familial amyotrophic lateral sclerosis (fALS) (Rosen et al. 
1993) led to the development of the SOD1G93A transgenic mouse model of 
ALS, in which mice overexpress multiple copies of human SOD1G93A 
(Gurney et al. 1994). Numerous mouse models have since been developed 
expressing one of 20 different types of mutations in the SOD1 gene  
(Picher-Martel et al. 2016). Nonetheless, the SOD1G93A mouse model 
remains the most widely used model for in vivo studies (Lu et al. 2016). 
SOD1G93A mice generally display hind limb weakness (the first clinical sign 
of ALS) at 3-4 months of age and are completely paralyzed by 5 months of 
age (Gurney et al. 1994). However, the onset of ALS varies greatly, 
depending on the genetic background and gender of mice (Pfohl et al. 2015). 
ALS in SOD1G93A mice resembles many features of ALS in humans, 
including axonal and neuromuscular dysfunction, activation of microglia 
(microgliosis) and astrocytes (astrogliosis), and motor neuron loss 
(McGoldrick et al. 2013). Thus, SOD1G93A mice serve as an important tool 
in the investigation of therapeutics in ALS.  
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3.1.2 Role of the P2X7 receptor in neuroinflammation in ALS 
Neuroinflammation is one of the important factors that contribute to the 
progression of ALS (Hooten et al. 2015). The adenosine 5’-triphosphate 
(ATP)-P2X7 receptor signalling axis has an emerging role during the 
symptomatic stages of ALS. P2X7 receptor can drive microglial activation 
and proliferation, potentially leading to a deleterious cycle of 
neuroinflammation and neurodegeneration (Monif et al. 2010). The P2X7 
receptor is upregulated in the spinal cords of ALS patients (Yiangou et al. 
2006) and of SOD1G93A rats (Casanovas et al. 2008). The upregulation of the 
P2X7 receptor has also been reported in primary microglia from SOD1G93A 
mice (D'Ambrosi et al. 2009). Moreover, the activation of the P2X7 receptor 
on microglia expressing SOD1G93A or to a lesser extent wild-type microglia, 
causes death of neuronal cells (D’Ambrosi et al. 2009). Similarly, the 
activation of P2X7 receptor on SOD1G93A or wild-type astrocytes causes 
death of motor neurons (Gandelman et al. 2010).  
3.1.3 JNJ-47965567 
JNJ-47965567 is a highly specific and potent central nervous system  
(CNS)-penetrant P2X7 antagonist which can impair murine P2X7 with a half 
maximal inhibitory concentration of 2 nM (Bhattacharya et al. 2013, Letavic 
et al. 2013). The brain to plasma ratio of JNJ-47965567 is approximately 1, 
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which indicates that this compound can readily penetrate the CNS 
(Bhattacharya and Biber 2016). Since JNJ-47965567 has demonstrated 
therapeutic efficacy in CNS disorders such as temporal lobe epilepsy 
(Jimenez-Pacheco et al. 2016) and neuropathic pain (Bhattacharya et al. 
2013), it is an ideal P2X7 receptor antagonist to impair this receptor in other 
disease models characterised by neuroinflammation including ALS.  
3.1.4 Aims 
The current study hypothesised that the highly specific and potent  
CNS-penetrant P2X7 receptor antagonist, JNJ-47965567, may demonstrate 
therapeutic efficacy in ALS. Thus, this study aimed to determine if 
pharmacological blockade of the P2X7 receptor with JNJ-47965567 
ameliorates disease progression in SOD1G93A mice.  
3.2 Methods 
3.2.1 Reagents 
Food pellets were from Specialty Feeds (Glen Forrest, WA, Australia). 
HydroGel packs were from ClearH2O (Westbrook, ME, USA).  
(2-Hydroxypropyl)-beta-cyclodextrin (β-CD) and paraformaldehyde (PFA) 
were from Sigma-Aldrich (St. Louis, MO, USA). JNJ-47965567 was from 
Tocris Bioscience (Ellisville, MO, USA). Dulbecco’s phosphate buffered 
saline (PBS) was from Thermo Fisher Scientific (Waltham, MA, USA). 
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3.2.2 Animals  
All animal experiments were conducted in accordance with the Animal 
Ethics Committee of the University of Wollongong (Wollongong, Australia) 
(AE16/18). B6SJL-Tg(SOD1-G93A)1GUr/j transgenic ALS mice 
hemizygous for the human SOD1G93A transgene and backcrossed onto 
C57BL/6J background were originally provided by Bradley Turner 
(University of Melbourne, Melbourne, Australia). Mice were bred and 
maintained at the Australian BioResources Animal Facility (Moss Vale, 
Australia). Forty-eight SOD1G93A mice aged between 34-75 days were 
delivered to the Rodent Facility at the University of Wollongong 
(Wollongong, Australia). The relative copy number of the SOD1G93A 
transgene was assessed by polymerase chain reaction (PCR) of tail-tip 
samples (provided by Australian BioResources) as described  
(Bartlett et al. 2017). The relative SOD1G93A transgene copy number was 
similar between groups (Dr Diane Ly, personal communication). Mice were 
housed in a temperature-controlled environment on a 12:12 h light-dark 
cycle in digital ventilated cages (Techniplast, Buguggiate, Italy). Male mice 
were housed 1-3 per cage, whereas female mice were housed 2-4 per cage. 
Due to fighting, all grouped males were eventually separated and housed 
individually before the end of the study period. Food and water were 
provided ad libitum. When mice were unable to access food and water easily  
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(i.e., clinical score 2) water bottles with long sippers were used, and 
moistened food pellets and HydroGel packs were placed on the bottom of 
the cages. 
3.2.3 Treatments 
β-CD was prepared at 0.3 g/mL (30% m/v) in Milli-Q water (vehicle 
solution). JNJ-47965567 was solubilised in vehicle solution at 5 mg/mL by 
mixing at 45oC for 2 hours and heated sonication for 15 minutes. Both 
solutions were filter-sterilised through 0.22 µm filters (Millex GP, 
Darmstadt, Germany). Both vehicle and drug were prepared weekly and 
stored at 4◦C until required. Cohorts of 24 mice were injected with  
JNJ-47965567 (30 mg/kg) or 30% vehicle solution intraperitoneally (i.p.) 
three times a week from 101-103 days (d) of age (i.e., disease onset) until 
end-stage using Omnican 0.5 mL syringes fitted with 30G needles (Braun, 
Melsungen, Germany). Repeat injections were performed on alternating 
sides of the abdomen to minimise irritation. Each group consisted of equal 
numbers of male and female SOD1G93A mice (12 males and 12 females per 
group) matched for age and sex according to ALS Therapy Development 
Institute (Scott et al. 2008) and the European ALS/MND Group (Ludolph  
et al. 2010) guidelines. One vehicle-treated male mouse died from an 
unexpected event unrelated to ALS and was excluded from all analysis. 
Throughout the drug trial, researchers were blinded to treatments. 
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3.2.4 Animal monitoring 
SOD1G93A mice were monitored for body weight, clinical score and motor 
coordination (rotarod performance) (Bartlett et al. 2017). All these 
parameters were assessed from 41-80 d of age in the morning to minimise 
changes due to diurnal variations. Only data from d 80 was included in 
analyses, except for rotarod performance, which was from d 95 to obtain at 
least two training sessions prior to recording data. 
3.2.4.1 Body weight measurement  
Body weight loss is a sensitive indicator of disease progression in SOD1G93A 
mice (Cervetto et al. 2013, Hatzipetros et al. 2015). Prior to injection, body 
weight was assessed three times a week using an OHAUS Explorer precision 
balance (Parsippany, NJ, USA). The maximum body weight recorded 
between 80-101 d for each mouse was taken as the pre-treatment maximum 
body weight of each mouse and used to calculate the percentage body weight 
change for each mouse at each subsequent time-point.  
3.2.4.2 Clinical scoring 
To assess changes in neuromuscular function of SOD1G93A mice, mice were 
scored three times a week using criteria based on that of the ALS Therapy 
Development Institute (Table 3.1) (Hatzipetros et al. 2015).   
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Table 3.1 Clinical scoring system for SOD1G93A mice 
Score Criteria 
0 When mouse is suspended by the tail, the hindlimb is fully extended away from the lateral midline 
1 When mouse is suspended by the tail, the hindlimb is collapsed partially or fully towards lateral midline  
2 
When mouse is allowed to walk, toes curl downwards at least 
twice during walking OR any part of the foot is dragging along 
cage bottom/table 
3 When mouse is allowed to walk there is a forward motion however the hindlimb is not being used for forward motion 
4 When the mouse is placed on its either side it is not able to right itself within 10 seconds from either side 
3.2.4.3 Rotarod performance 
Rotarod performance was used to measure motor coordination of mice once 
per week. Prior to disease onset, mice were trained at least twice using a  
five-lane accelerating rotarod (RotaRod Advanced, TSE Systems, Hesse, 
Germany). For training sessions, the rod was rotated at a constant speed of 
10 revolutions per minute (rpm), followed by three runs during which the 
rod gradually increased speed from 4-20 rpm over 180 seconds (s), with a  
30 s rest interval between runs. For testing, the rod was rotated at a constant 
speed of 4 rpm for 5 s, followed by three runs with the rod rotating from  
4-20 rpm over 180 s, with a 30 s rest interval between runs. Each mouse on 
each test day was given three attempts and the maximum time that each 
mouse remained on the rod was recorded as the latency to fall and included 
in the data analysis. As disease progressed (i.e., clinical score 2), mice were 
unable to stand on the rod for which the latency to fall was recorded as 5 s.  
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 3.2.5 Survival 
Mice were euthanised by slow-fill carbon dioxide inhalation technique when 
they reached the ethically approved endpoint of either 20% body weight loss 
compared to their initial pre-treatment maximum body weight or when they 
were unable to right themselves within 10 s after being placed on either side 
(i.e., a score of 4).  
Following euthanasia, mice in each treatment cohort were equally divided 
into one of two groups for tissue processing, with age-, sex-matched pairs 
treated in the same fashion. Whole blood was collected from all mice via 
cardiac puncture. Serum was collected by centrifuging blood for 10 minutes 
at 14,000 x g and storing the cell-free supernatants at -800C. Mice were then 
either perfused with 50 ml PBS, or with 25 ml PBS followed by 25 ml 4% 
(m/v) PFA in PBS. Spinal cords and brains from PBS-perfused mice were 
stored at -800C. Spinal cords and brains from PFA-perfused were further 
fixed with 4% PFA/PBS overnight at 40C followed by incubation in 30% 
(m/v) sucrose/PBS for another night (or until tissue has sunk to the bottom) 
at 40C and then stored at -800C. All sera, spinal cords and brains were 
archived for future analyses, which was beyond the time frame of the current 
project.  
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3.2.6 Data analysis 
All analyses were performed using GraphPad Prism 5.0 (San Diego, CA, 
USA). Data are presented as mean ± standard deviation (SD). Differences in 
survival between groups were compared by a log-rank (Mantel–Cox) test. 
For body weight, the differences between groups were analysed using 
unpaired Student’s t-test for the mean body weight percentage for each 
mouse over entire period of the study. For clinical score and motor 
coordination, differences between groups were compared using a two-way 
ANOVA for each mouse at each recorded time-point. Statistical differences 
were considered significant when P < 0.05.  
3.3 Results 
3.3.1 ALS progression was continuous and gender dependent in 
SOD1G93A mice 
3.3.1.1 ALS progressed continuously from disease onset until end-stage 
in SOD1G93A mice 
SOD1G93A mice were treated with vehicle solution or JNJ-47965567 from 
101-103 d (i.e., disease onset) until end-stage. SOD1G93A mice were 
monitored for the progression of ALS by measuring body weight, clinical 
score, motor coordination and survival (n = 23, Figure 3.1). Body weight 
measurements and clinical score according to the criteria outlined by the 
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ALS Therapy Development Institute (Table 3.1) were assessed three times a 
week. Motor coordination was measured by rotarod test once a week using 
a five-lane accelerating rotarod. Survival of SOD1G93A mice was determined 
by one of two criteria; either when SOD1G93A mice lost 20% body weight 
compared to their initial pre-treatment maximum body weight, or when mice 
were unable to right themselves within 10 s after being placed on either side 
(i.e., a score of 4). To explore disease progression in SOD1G93A mice, the 
vehicle-treated (control) mice are described first below.  
The average clinical score of vehicle-treated SOD1G93A mice at d 80 was 0 
with only one mouse with a clinical score of 1. As clinical score increased 
gradually, vehicle-treated mice attained average scores of 1 and 2 at d 139 
and d 160, respectively. Out of the 23 vehicle-treated mice, only eight mice 
were assigned a clinical score greater than 2. The average clinical score 
plateaued at a mean score of 2.8 (Figure 3.1 A). On average, vehicle-treated 
mice gained weight until d 106 and then declined continuously from d 108 
without recovering at any subsequent time points. Body weight declined 
gradually from d 108 until d 139, which decreased drastically from d 139 
until end-stage (Figure 3.1 B). Similarly, vehicle-treated mice showed 
improvements in motor coordination from d 95 to d 123, but this dropped 
after d 123 (Figure 3.1 C). The average survival of vehicle-treated mice was 
found to be 163 ± 8.8 d. The first mouse reached end-stage at  
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d 143 followed by a subsequent decline in survival until d 177  




















Figure 3.1 ALS progressed continuously from disease onset until end-stage in 
SOD1G93A mice. SOD1G93A mice were injected intraperitoneally with vehicle from  
d 101-103 (i.e., disease onset) (↓) three times per week until end-stage of disease. (A) 
Clinical score and (B) body weight were measured three times per week from d 80. (C) 
Motor coordination was assessed once per week from d 95 by rotarod test and presented 
as latency to fall. (D) Survival was determined either by 20% body weight loss compared 
to their initial pre-treatment maximum body weight or when mice were unable to right 
themselves within 10 s after being placed on either side (i.e., a score of 4). Data is 
presented as mean ± SD (n = 23).  
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3.3.1.2 ALS progressed more rapidly in male than female SOD1G93A 
mice  
Gender differences in the progression of ALS in SOD1G93A mice have been 
reported previously (Choi et al. 2008, Olivan et al. 2015). Thus, the 
parameters above were compared between male and female vehicle-treated 
SOD1G93A mice (n = 11,12; Figure 3.2). Average ALS scores over the course 
of the study were similar between male and female mice (P = 0.99,  
Figure 3.2 A). Likewise, there was no significant difference in motor 
coordination between male and female mice (P = 0.47, Figure 3.2 C). In 
contrast, weight loss in male mice was greater than in female mice  
(Figure 3.2 B). In addition, male mice had significantly lower mean 
percentage body weight than female mice when calculated for each mouse 
over the entire study period (P = 0.01, Figure 3.2 B Inset). Moreover, 
survival was significantly shorter in male (161 ± 4.4 d) compared to female 
mice (165 ± 11.3 d) (P = 0.01, Figure 3.2 D).  
3.3.2 JNJ-47965567 treatment did not alter ALS progression in 
SOD1G93A mice 
3.3.2.1 JNJ-47965567 treatment did not alter ALS progression in 











Figure 3.2 ALS progressed more rapidly in male than female SOD1G93A mice. 
SOD1G93A mice were injected intraperitoneally with vehicle from d 101-103 (i.e., disease 
onset) (↓), three times per week until end-stage of disease. (A) Clinical score and (B) 
body weight were measured three times per week from d 80. Inset shows the mean body 
weight over the entire study period. (C) Motor coordination was assessed once per week 
from d 95 by rotarod test and presented as latency to fall. (D) Survival was determined 
either by 20% body weight loss compared to their initial pre-treatment maximum body 
weight or when mice were unable to right themselves within 10 s after being placed on 
either side (i.e., a score of 4). Comparisons between male and female mice were done 
using (A and C) two-way ANOVA analysis, (B) unpaired Student’s t-tests over the entire 
study period or (D) a log-rank (Mantel–Cox) tests. Data is presented as mean ± SD  
(n = 11 males and n = 12 females). * P < 0.05. 
Next, ALS progression was compared between JNJ-47965567- and  
vehicle-treated SOD1G93A mice (n = 23-24, Figure 3.3). Clinical scores were 
similar between JNJ-47965567- and vehicle-treated SOD1G93A mice.  
JNJ-47965567-treated mice had an average clinical score of 1 at d 132, 
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which then increased to an average clinical score of 2 at d 162, after which 
the average clinical score slowly increased. This was similar to  
vehicle-treated mice (P = 0.724, Figure 3.3 A). Measurements also revealed 
similar trends in body weight loss for JNJ-47965567-treated mice compared 
to vehicle-treated mice. JNJ-47965567-treated mice began to lose body 
weight from d 111 with a rapid decline observed from d 139, which is similar 
to the vehicle-treated mice (Figure 3.3 B). In addition, no difference in mean 
percentage body weight were observed between JNJ-47965567- and  
vehicle-treated mice when calculated over the entire study period  
(P = 0.303, Figure 3.3 B Inset). Motor coordination was also similar between 
JNJ-47965567-treated and vehicle-treated SOD1G93A mice (P = 0.731).  
JNJ-47965567-treated mice followed a similar pattern in decline of motor 
coordination from d 139 as described above for vehicle-treated mice  
(Figure 3.3 C). Finally, JNJ-47965567 treatment failed to extend the average 
survival of mice (165 ± 10.3 d) compared to vehicle treatment (163 ± 8.8 d)  
(P = 0.345, Figure 3.3 D). The rate of decline in survival was also similar 
between these two treatments (Figure 3.3 D). 
3.3.2.2 JNJ-47965567 delayed clinical score progression in female 















Figure 3.3 JNJ-47965567 treatment did not alter ALS progression in SOD1G93A 
mice. SOD1G93A mice were injected intraperitoneally either with 30 mg/kg JNJ-47965567 
or with vehicle from d 101-103 (i.e., disease onset) (↓), three times per week until disease 
end-stage. (A) Clinical score and (B) body weight were measured three times per week 
from d 80. Inset shows the mean body weight over the entire study period. (C) Motor 
coordination was assessed once per week from d 95 by rotarod test and presented as 
latency to fall. (D) Survival was determined either by 20% body weight loss compared to 
their initial pre-treatment maximum body weight or when mice were unable to right 
themselves within 10 s after being placed on either side (i.e., a score of 4). Comparisons 
between vehicle- and JNJ-47965567-treated mice were done using (A and C) two-way 
ANOVA analysis (B) unpaired Student’s t-tests over the entire study period (D) a  
log-rank (Mantel–Cox) tests. Data is presented as mean ± SD (n = 23 vehicle-treated mice 
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Previous studies have reported gender-dependent effects of P2X7 receptor 
antagonism in SOD1G93A mice (Cervetto et al. 2013, Bartlett et al. 2017). 
Moreover, the data above revealed gender differences in disease progression 
in vehicle-treated SOD1G93A mice (Figure 3.2). Therefore, the effect of  
JNJ-47965567 treatment was analysed in male and female SOD1G93A mice 
separately. Analysis of male mice showed similar clinical score curves for 
both vehicle- and JNJ-47965567-treated male mice (P = 0.653,  
Figure 3.4 A). In contrast, JNJ-47965567 treatment delayed a rise in the 
clinical score in female SOD1G93A mice. JNJ-47965567-treated female mice 
stayed longer at average clinical score of 1 from d 132 to d 148 and had lower 
clinical score from d 141 until end-stage compared to vehicle-treated female 
mice (Figure 3.4 A). However, this difference in clinical score between 
treatments in female mice failed to reach statistical significance (P = 0.297). 
Body weight loss and motor coordination in JNJ-47965567-treated male or 
female mice were not significantly different to corresponding vehicle-treated 
male and female mice, respectively (body weight loss: males P = 0.435, 
females P = 0.407, Figure 3.4 B and Inset; rotarod performance: males 
 P = 0.663, females P = 0.378, Figure 3.4 C). Moreover, there was no 
difference in survival between treatments in either male or female mice 
(males: vehicle 161 ± 4.4 d vs. JNJ-47965567 163 ± 12 d, P = 0.222, 
 Figure 3.4 D; females: vehicle 165 ± 11.3 d vs. JNJ-47965567 167 ± 8.6 d, 
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Figure 3.4 JNJ-47965567 delayed clinical score progression in female SOD1G93A 
mice but was not statistically significant. SOD1G93A mice injected intraperitoneally 
either with 30 mg/kg JNJ-47965567 or with vehicle from d 101-103 (i.e., disease onset) 
(↓), three times per week until end-stage of disease. (A) Clinical score and (B) body 
weight were measured three times per week from d 80. Inset shows the mean body weight 
over the entire study period. (C) Motor coordination was assessed once per week from  
d 95 by rotarod test and presented as latency to fall. (D) Survival was determined either 
by 20% body weight loss compared to their initial pre-treatment maximum body weight 
or when mice were unable to right themselves within 10 s after being placed on either 
side (i.e., a score of 4). Comparisons between vehicle- and JNJ-47965567-treated mice 
were done using (A and C) two-way ANOVA analysis (B) unpaired Student’s t-tests over 
the entire study period, and (D) a log-rank (Mantel–Cox) tests.  Data is presented as  
mean ± SD (n = 11-12 males and n = 12 females per treatment). 
3.3.2.3 JNJ-47965567 treatment did not alter the frequency of days spent 
at a given clinical score in SOD1G93A mice  
The above data (Figure 3.4 A) suggests that clinical score may differ between  
vehicle- and JNJ-47965567-treated mice. Therefore, to examine the clinical 
score data in an alternate fashion, this data was re-examined as the length of 
time each mouse received a score of 1, 2 or 3. However, no differences were 
observed between treatments in mice when combined or when examined by 
gender (Figure 3.5). Both female and male combined mice received a clinical 
score of 1 for an average of 22.3 d. Moreover, female and male mice, on 
average, received clinical scores of 2 and 3 for 2.7 d and 0.5 d, respectively 
(Figure 3.5 A). Similar results were observed in male (Figure 3.5 B) and 


















Figure 3.5 JNJ-47965567 treatment did not alter the frequency of days spent at 
clinical score 1, 2 and 3 in SOD1G93A mice. SOD1G93A mice were injected 
intraperitoneally either with 30 mg/kg JNJ-47965567 or with vehicle from d 101-103 (i.e., 
disease onset), three times per week until end-stage of disease. Clinical score was 
measured three times per week from d 80. The frequency of days spent at a clinical score 
of 1, 2 or 3 for each mouse from vehicle- and JNJ-47965567-treated group are shown as 
(A) all, (B) male, (C) or female vehicle- and JNJ-47965567-treated mice. Symbols 
represent individual mice and bars represent group means (n = 11-12 males and n = 12 
females per treatment). 
3.4 Discussion 
The current study showed that the CNS-penetrant P2X7 receptor antagonist  
JNJ-47965567 does not alter disease progression in ALS SOD1G93A mice. 

















































































combined into treatment groups of both genders. The progression of ALS in 
SOD1G93A mice however was found to be continuous from disease onset and 
gender dependent, with disease progression more rapid in males than 
females. 
3.4.1 ALS progression is gender-dependent in SOD1G93A mice 
In this study, the progression of ALS in SOD1G93A mice was gender 
dependent, with a more rapid disease progression in male than female mice. 
This result correlates with findings of previous studies (Choi et al. 2008, 
Alves et al. 2011, Cervetto et al. 2013, Olivan et al. 2014). Similar gender 
differences also exist in human ALS, with males more prone to ALS than 
females (McCombe and Henderson 2010). Delayed disease onset and 
prolonged survival in SOD1G93A females is most likely due to the 
contribution of the genetic background (Heiman-Patterson et al. 2005, Pfohl  
et al. 2015) and/or the protective roles of the sex hormone, estrogen (Choi  
et al. 2008). The current study used mice on a B6SJL background. From an 
analysis of 97 studies, gender differences in this hybrid strain have been 
reported previously, in which female SOD1G93A mice experienced delayed 
disease onset and extended lifespans compared to male SOD1G93A mice 
(Pfohl et al. 2015). Whilst other studies have shown advanced disease onset 
and shortened lifespan in ovariectomized female compared to sham-operated 
female SOD1G93A mice (Choi et al. 2008, Yan et al. 2018). Moreover, 
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treatment of ovariectomized female SOD1G93A mice with the estrogen,  
17b-estradiol, delayed disease progression and extended survival in these 
mice (Choi et al. 2008). Combined this supports a role for estrogens in 
reducing ALS in female SOD1G93A mice. Thus, these findings reemphasize 
the need to consider gender difference in pre-clinical studies of ALS. 
3.4.2 JNJ-47965567 treatment did not alter ALS progression in 
SOD1G93A mice 
In this study, treatment of SOD1G93A mice with JNJ-47965567 (30 mg/kg) 
from disease onset failed to slow disease progression and extend survival 
compared to vehicle-treated mice. JNJ-47965567, at the same dose  
(30 mg/kg), reduced clinical symptoms, and microgliosis and astrogliosis in 
a murine model of epilepsy (Jimenez-Pacheco et al. 2016). During the course 
of the current study, another CNS-penetrant P2X7 receptor antagonist,  
A-804598 (30 mg/kg) from pre-disease onset, d 100, was also shown to have 
no effect in slowing disease progression, delaying disease onset or extending 
survival in SOD1G93A mice (Fabbrizio et al. 2017). Combined, these two 
studies suggest that P2X7 receptor antagonism in the CNS and periphery is 
insufficient to ameliorate ALS progression in SOD1G93A mice. These 
findings parallel observations in SOD1G93A mice in which constitutive 
genetic deletion of P2X7 failed to delay ALS progression (Apolloni et al. 
2013a). However, it cannot be excluded that alternate doses and/or regimes 
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with JNJ-47965567 (or A-804598) may reduce disease progression in 
SOD1G93A mice. Thus, future studies in SOD1G93A could consider higher 
doses, more frequent injections and/or alternate routes of administration of 
the compounds. 
The above findings with two different CNS-penetrant P2X7 receptor 
antagonists contrasts the three previous studies with the non-CNS-penetrant 
P2X7 receptor antagonist Brilliant Blue G (BBG) in SOD1G93A mice 
(Cervetto et al. 2013, Apolloni et al. 2014, Bartlett et al. 2017). In the first 
study, treatment of SOD1G93A mice with BBG (45.5 mg/kg) at disease onset 
improved motor coordination in both male and female separately, and 
delayed weight loss in male mice and both genders combined (Cervetto  
et al. 2013). In the second study, administration of BBG (50 mg/kg)  
post-disease onset improved motor coordination, and administration of BBG 
(250 mg/kg) from this same time point improved both clinical score and 
motor coordination. The effect of BBG was independent of gender (Apolloni 
et al. 2014). In the third study, administration of BBG (45.5mg/kg) at late 
pre-disease onset delayed weight loss in female mice and both genders 
combined, and extended survival in female mice (Bartlett et al. 2017).  
Reasons for the observed differences between JNJ-47965567 (this study) or 
A-804598 (Fabbrizio et al. 2014) and BBG (Cervetto et al. 2013, Apolloni 
et al. 2014, Bartlett et al. 2017) remain unknown. JNJ-47965567 and  
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A-804598 are more potent antagonists of the P2X7 receptor compared to 
BBG (Bhattacharya and Biber 2016). Thus, given the commencement and 
frequency of drug administration, and injection route was similar between 
each of the studies in SOD1G93A mice, it appears unlikely that this is a major 
cause for the observed differences between JNJ-47965567 (or A-804598) 
and BBG. However, differences in tissue distribution and pharmacokinetics 
between these compounds are unknown and cannot be excluded. One 
possible explanation for the differences observed between JNJ-47965567 (or 
A-804598) and BBG may relate to their ability to penetrate the CNS. Both 
JNJ-47965567 and A-804598 are CNS-penetrant, whilst BBG is  
non-CNS-penetrant (Bhattacharya and Biber 2016). Thus, this data 
combined suggests that blockade of systemic P2X7 receptor can ameliorate 
ALS progression in SOD1G93A mice (as seen with BBG), but that the effect 
is lost when CNS P2X7 is also blocked (as seen with JNJ-47965567 or  
A-804598). If true, this indicates systemic P2X7 receptor activation can 
promote ALS, whilst CNS P2X7 receptor activation protects against ALS 
progression. In support of this concept and as mentioned above, genetic 
deletion of the P2X7 receptor in SOD1G93A mice failed to protect against 
ALS and in fact worsened disease progression (Apolloni et al. 2013a). An 
alternate explanation for the observed differences between JNJ-47965567 
(or A-804598) and BBG in SOD1G93A mice is differences in P2X7 receptor 
selectivity. Both JNJ-47965567 and A-804598 are highly selective P2X7 
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receptor antagonists (Bhattacharya et al. 2013, Donnelly-Roberts et al. 
2009). In contrast, BBG is a non-selective P2X7 receptor antagonist, which 
can also block other P2X receptors (Jiang et al. 2000), the ATP release 
channel pannexin-1 (Qiu and Dahl 2009) and sodium ion channels (Jo and 
Bean 2011). Thus, the possibility remains that BBG acts on at least one of 
these other molecules in the periphery to ameliorate ALS progression in 
SOD1G93A mice. 
In the current study, 30% β-CD was used as a vehicle solution. Cyclodextrins 
are commonly used as drug vehicles because of their increased aqueous 
solubility, stability, bioavailability and reduced irritation (Shimpi et al. 
2005). However, cyclodextrins such as methyl-beta-cyclodextrin can deplete 
cholesterol in the lipid rafts of plasma membranes (Al Azzam and 
Muhammad 2015). Notably, cholesterol is a negative regulator of P2X7 
receptor pore formation interacting directly via the transmembrane domains 
of the P2X7 receptor (Robinson et al. 2014, Karasawa et al. 2017). Thus, the 
possibility remains that administration of β-CD in SOD1G93A mice enhanced 
P2X7 receptor activity in these animals and circumvented any inhibitory 
benefits associated with JNJ-47965567. However, short-term incubation 
with β-CD did not alter ATP-induced ethidium+ uptake into EOC13 
microglia compared to EOC13 microglia pre-incubated in the absence of  
β-CD (section 2.3.2.2). Nevertheless, future studies could examine if  
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long-term β-CD increases P2X7 receptor activation in vitro or in vivo. 
JNJ-47965567, prepared in cyclodextrin-base vehicles, has therapeutic 
benefits in vivo (Bhattacharya et al. 2013; Jimenez-Pacheco et al. 2016). 
Whilst β-CD is a Food and Drug Administration (FDA)- and Therapeutic 
Goods Administration (TGA)-approved drug vehicle (Loftssona and 
Brewsterb 2010). Thus β-CD was selected for use in vivo. In the current 
study, SOD1G93A mice treated with either β-CD or JNJ-47965567 displayed 
unexpected side-effects including eye discharge, hair loss and ear necrosis 
(results not shown). Given this occurred in both treatment groups, this 
indicates that these side-effects were most likely due to β-CD rather than the 
antagonist. Furthermore, these side-effects were observed only from  
d 150 (results not shown) suggesting that these were a result of chronic 
treatment with β-CD. To the best of our knowledge, such side effects have 
not been reported for β-CD but the current study suggests the ethical use of 
β-CD needs to be further considered in any future long-term studies with this 
vehicle.  
3.4.3 Limitations 
3.4.3.1 End points criteria 
In the current study, the ethical end point of SOD1G93A mice was determined 
by one of two criteria; either, when SOD1G93A mice lost 20% body weight 
86  
compared to their initial pre-treatment maximum body weight, or when mice 
were unable to right themselves within 10 s after being placed on either side 
(i.e., a score of 4). In this study, most mice reached endpoint due to 20% 
weight loss with few mice obtaining clinical scores of 2, 3 or 4. This limited 
the study of disease progression, especially during the initial stages of the 
disease, which may have eliminated the possibility of JNJ-47965567 
delaying disease progression towards end-stage. Although the use of these 
two end points has been recommended by the ALS Institute (Ludolph et al. 
2007, Scott et al. 2008), more appropriate criteria for end points may need 
to be argued with ethics committees to study the efficacy of drug treatments 
in SOD1G93A mice.  
3.4.3.2 Rotarod test  
Rotarod tests are the most frequently used test to monitor motor coordination 
in ALS mice (Weydt et al. 2003). In the current study, the performance of 
SOD1G93A mice in the rotorod test was highly variable. This may reflect 
inexperience with this technique. Variability in rotarod performance may 
also be due to receiving mice at different ages leading to the younger mice 
having more trial runs than older mice before disease onset.  In order to 
detect deficits in motor coordination more accurately by the rotarod test, all 
mice should receive equal number of training sessions or runs before starting 
the experiment (Miana-Mena et al. 2005).  
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Despite the extensive use of rotarod test in ALS studies, this test is 
considered insensitive to detect motor deficits prior to the onset of clinical 
symptoms (Knippenberg et al. 2010).  Thus, other tests such as  
the Hanging-wire test or foot print analysis could be adopted. These tests are 
more reliable and accurate in detecting early motor deficits without the need 
for training the mice and are less time consuming than the rotarod test 
(Olivan et al. 2014, Knippenberg et al. 2010). 
3.4.4 Conclusions 
In conclusion, the CNS-penetrant, selective P2X7 receptor antagonist  
JNJ-47965567 failed to alter disease progression in SOD1G93A mice. This 
data parallels another study using a second CNS-penetrant, the selective 
P2X7 receptor antagonist, A-804598 (Fabbrizio et al. 2017). Both studies 
contrasted the three studies performed with the non-CNS penetrant,  
non-selective P2X7 receptor antagonist BBG (Cervetto et al. 2013, Apolloni 
et al. 2014, Bartlett et al. 2017). Combined, these studies suggest that 
blockade of systemic, but not the CNS P2X7 receptors, or blockade of 























Amyotrophic lateral sclerosis (ALS) is a complex, progressive and fatal 
motor neuron disease. Even after decades of research, the primary factors 
that trigger ALS remain unknown. Among the different factors contributing 
to the progression of ALS, the involvement of the  
adenosine 5’-triphosphates (ATP)-P2X7 receptor signalling axis plays a role 
in this disease through the activation of microglia and astrocytes to promote 
the death of motor neurons (sections 1.3.1 and 1.3.2). The role of the P2X7 
receptor in ALS progression has been demonstrated using the P2X7 receptor 
antagonist, Brilliant Blue G (BBG), in superoxide dismutase-1G93A 
(SOD1G93A) mice (section 1.3.3). Cellular models that closely resembles 
ALS-associated models would be beneficial to establish to further 
understand the roles of the ATP-P2X7 receptor signalling axis in ALS. 
Furthermore, the use of P2X7 receptor antagonists with greater potency, 
selectivity and central nervous system (CNS) penetration in vivo may assist 
in further establishing the role of the P2X7 receptor in ALS progression. 
Thus, this study is set out to (i) investigate EOC13 microglia as a potential 
in vitro model of the ATP-P2X7 receptor signalling axis in ALS-associated 
microglia (Chapter 2); and (ii) to test the therapeutic potential of P2X7 
receptor blockade using the CNS-penetrant, selective P2X7 antagonist,  
JNJ-47965567, in reducing ALS progression in SOD1G93A mice (Chapter 3).  
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4.2 Conclusions and significance 
In Chapter 2, EOC13 microglia were found to express high and low amounts 
of P2X7 receptors and CD39, respectively. These amounts correlated with 
high and low P2X7 receptor and ectoATPase activity, respectively. These 
findings parallel that of ALS-associated microglia. P2X7 receptors are  
up-regulated on microglia in human and rodent ALS spinal cords and on 
microglia from SOD1G93A mice (Yiangou et al. 2006, Casanovas et al. 2008, 
D’Ambrosi et al. 2009), while microglia from SOD1G93A mice express low 
ectoATPase activity (D’Ambrosi et al. 2009). Given these similarities, 
EOC13 microglia provide a potential model of ALS-associated microglia to 
study the role of the ATP-P2X7 receptor signalling axis in ALS in vitro. The 
activation of P2X7 receptors present on ALS-associated microglia results in 
the release of (unknown) cytotoxic factors which lead to the death of 
neuronal cell lines (D’Ambrosi et al. 2009). Thus, it would be of future 
importance to determine if P2X7 receptor activation on EOC13 microglia 
also results in the release of neurotoxic factors, and then to use EOC13 
microglia to identify these unknown factors. In this regard it would also be 
of importance to further characterise the phenotype of EOC13 cells given the 
dual role of microglia in ALS (toxic versus protective phenotype) (Liao  
et al. 2012, Geloso et al. 2017). The availability of an in vitro model of  
ALS-associated microglia may facilitate the study of molecular mechanisms 
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associated in ALS, which in turn may facilitate the identification of potential 
therapeutic targets to prevent ALS progression in vivo. 
In Chapter 3, the administration of JNJ-47965567 into SOD1G93A mice from 
clinical disease onset failed to alter disease progression. This result 
paralleled a second study using the CNS-penetrant, selective P2X7 
antagonist A-804598 in SOD1G93A mice (Fabbrizio et al. 2017). This study 
was published during the course of the JNJ-47965567 trial, but similarly 
showed no effect on ALS progression. These two studies contrast other work 
with the non-CNS penetrant, non-selective P2X7 antagonist BBG, which 
showed efficacy in reducing ALS progression in SOD1G93A mice (Cervetto 
et al. 2013, Apolloni et al. 2014, Bartlett et al. 2017). Findings from these 
five studies suggest that the blockade of systemic (peripheral) P2X7 receptor 
can ameliorate ALS progression in SOD1G93A mice, but that this effect is lost 
when the CNS P2X7 receptor is also blocked. It will be of future value to 
directly compare the effect of JNJ-47965567 and BBG in SOD1G93A mice 
simultaneously to validate a role for the systemic P2X7 receptors in ALS 
disease progression. If this concept is true it may suggest that P2X7 receptor 
activation in the CNS may be beneficial in slowing ALS. Thus, the study of 
this receptor in EOC13 microglia may reveal protective rather than cytotoxic 
roles in relation to neuronal cells.  
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An alternative reason for the observed difference between JNJ-47965567 (or 
A-804598) and BBG in SOD1G93A mice may be differences in P2X7 receptor 
selectivity. Both JNJ-47965567 (IC50 = 10 nM) and A-804598 (IC50 = 2 nM) 
are highly selective P2X7 receptor antagonists (Bhattacharya and Biber 
2016). In contrast, BBG is a non-selective P2X7 receptor antagonist capable 
of inhibiting other P2X receptors (Jiang et al. 2000), as well as the  
ATP-release channel pannexin-1 (Qiu and Dahl 2009) and sodium channels 
(Jo and Bean 2011). Thus, the possibility remains that BBG acts on channels 
other than P2X7 receptors to ameliorate ALS progression in SOD1G93A mice. 
Thus, it will also be of future value to compare the effect of BBG with other 
specific but non-CNS-penetrant P2X7 receptor antagonists, such as 
A740003 (Honore et al. 2006) in SOD1G93A mice to determine if systemic 
P2X7 receptor or other channels play a role in ALS progression. 
Greater understanding of the potential role of systemic and CNS P2X7 
receptors in ALS progression in SOD1G93A mice may in turn reveal 
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APPENDIX A: Supplementary methods  
LADMAC conditioned medium  
LADMAC cells were cultured in DMEM/F12 medium supplemented with 
10% FBS and 2 mM GlutaMAX at 37oC and 95% air/ 5% CO2 for 5-6 days. 
Cells and cultured medium were centrifuged (5 min at 300 x g). The  
cell-free supernatant was then filtered through 0.22 µm filters (Millex GP, 
Darmstadt, Germany) and stored at -20o C until required.  
Solutions  
Phosphate-buffered saline (PBS), pH 7.4  
137 mM Potassium chloride      0.2 g/L  
2.7 mM Potassium dihydrogen Phosphate   0.2 g/L 
10 mM Sodium chloride      8 g/L 
1.8 mM Disodium hydrogen phosphate   1.14 g/L  
ACK lysis buffer, pH 7.4 
155 mM NH4Cl       8.29 g/L 
10 mM KHCO3       1 g/L 
0.1 mM Na2EDTA       0.038 g/L  
4 X SDS-PAGE loading buffer 
0.5 M Tris-HCl (pH 6.8)      130 ml/L 
40 % Glycerol (w/v)      
8% SDS (w/v)       
0.02% Bromophenol blue (w/v)      
119  
 SDS-PAGE running buffer (10x)  
1.92 M Glycine       143 g/L 
35 mM Sodium dodecyl sulphate    10 g/L 
0.25 M Tris(hydroxymethyl)- methylamine   30 g/L  
Western transfer buffer  
150 mM NaCL       14.61 g/L  
20% Methanol (v/v)     
25 mM Tris (hydroxymethyl)methyl amine   3.02 g/L 
1 x Tris-buffered saline containing Tween-20  
192 mM Glycine       14.4 g/L  
10 mM Tris base       1.18 g/L 
10 mM Tris HCl       6.35 g/L  










APPENDIX B: Supplementary data  
Appendix B1: Protein concentrations in EOC13 cell lysates were 
determined with a BCA protein assay using increasing concentrations of 
bovine serum albumin as a standard (as indicated). Results are representative 
of two independent experiments. 



















Appendix B2: Standard curves for estimating phosphate and protein 
concentrations in the molybdite assay using increasing concentrations of 
KH2PO4 and bovine serum albumin as a standard (as indicated). Results are 
representative of two independent experiments. 
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